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AC  Apoptotic cells 
ACC  Acinar cell carcinomas 
AML  Acute myeloid leukemia 
ATP   Adenosine triphosphate 
BAD   Bcl- 2 associated death promoter 
Bcl-2  B cell lymphoma 2 
Bcl-XL   B cell lymphoma extra large 
BCSC  Breast cancer stem cells 
BRAF  B-Raf proto-oncogene serine/threonine kinase 
BRCA2  Breast cancer 2 
C1-TEN C1 domain containing phosphatase and TENsin homologue 
Cbl  Casitas B-lineage lymphoma 
CDKN2A Cyclin dependent kinase inhibitor 2A 
CI  Confidence Interval 
CLL   Chronic lymphatic leukemia 
CRN   Cancer registry of Norway 
CSC   Cancer stem cell 
DKK3   Dickkopf related protein 3  
DPC4  Deleted in pancreas cancer 4 
E-cadherin Epithelial cadherin 
ECM   Extracellular matrix 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
EMT    Epithelial to mesenchymal transition 
ERK   Extracellular signal regulated kinase 
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FGF   Fibroblast growth factor 
GAS6   Growth arrest spesific 6 
GEMM Genetically engineered mouse models 
GGCX  Gamma-glutamyl carboxylase 
GSK3   Glycogen synthase kinase 3  
HGF   Hepatocyte growth factor 
HIF   Hypoxia induced transcription factor  
ICD   International classification of diseases 
ICD-O-3  International classification of diseases for oncology 
IFNAR   Interferon α/β receptor 
IG  Immune globuline 
IGF   Insulin like growth factor 
IPMN  Intraductal papillary mucinous neoplasm 
IRR  Incidence rate ratio 
KO   Knockout 
KRAS  Kirsten rat sarcoma viral oncogene homolog 
LMWH Low molecular weight heparin 
MAPK  Mitogen activated protein kinase 
MET  Mesenchymal to epithelial transition 
miR  MicroRNA 
MK  Menaquinone 
MMP   Matrix metallo- proteinases 
N-cadherin Neural Cadherin 
NF-κB   Nuclear factor κB 
NK cells  Natural Killer cells 
NOAC  Non-vitamin k anticoagulant 
NorPD  Norwegian Prescription database 
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PAK1   P-21 activated kinase 
PanIN   Pancreatic intraepithelial neoplasias 
PI3K   Phosphoinosytol 3 OH kinase 
PD1  Programmed Death Protein 1 
PDAC   Pancreatic ductal adenocarcinoma 
PNET   Pancreatic neuroendocrine tumors 
PtdSer  Phosphatidylserine 
ROS   Reactive oxygen species 
RTK   Receptor tyrosine kinase 
sAXL   Soluble AXL  
SMAD4 SMAD family member no 4. 
SOCS   Suppressor of cytokine signaling 
Sp   specificity protein 
TAM   Tyro, AXL, Mer 
TERT   Telomerase reverse transcriptase 
TLR   Toll-like receptor 
TGF-β   Transforming growth factor β 
TNFα   Tumor necrosis factor α 
TNM  Tumor, Node, Metastasis 
VEGF-A   Vascular endothelial growth factor A 
VHL   Von Hippen Lindau protein 
VKOR   Vitamin K epoxide reductase 
VKDP   Vitamin K dependent proteins 
VSMC   Vascular smooth muscle cells 







Cancer is a major health issue all over the world. Cancer related deaths are one of the 
major causes of deaths, and are in > 90 % of the cases related to metastatic 
development, and spread of the cancer outside the primary location.  
The receptor tyrosine kinase AXL is closely associated with the development of cancer 
and the receptor is upregulated in many different cancer forms. Upregulation is 
associated with increased invasiveness, and poor overall survival.  
Warfarin is a known anticoagulant, which also is suitable as an AXL inhibitor. The 
warfarin-mediated inhibition of AXL is through the depletion of Vitamin K, with a 
subsequent inhibition of the γ-carboxylation of the Vitamin K dependent proteins in 
the body. GAS6, the ligand of AXL, is vitamin K dependent and will be unable to 
activate the receptor following warfarin treatment. 
In this thesis, we have worked with the warfarin-mediated inhibition of the receptor 
tyrosine kinase AXL. In five different mouse model systems, we have evaluated the 
effect of warfarin-mediated AXL-inhibition in the development and metastasis of 
pancreatic ductal adenocarcinoma. We also evaluated how warfarin-mediated AXL 
inhibition impacts on expression of EMT markers, and the ability of the cells to migrate 
and form colonies, which is a hallmark of cancer with metastatic properties.  
Further, we performed a register based cohort study using the Norwegian National 
Registry, the Cancer registry of Norway and the Norwegian prescription database. We 
investigated the cancer incidence in warfarin users compared to non-users in a broad 
segment of the Norwegian population, with a cohort comprising 1,2 million persons 
aged 52-82 years. 
Our work establishes AXL as an important driver of metastatic formation in pancreatic 
ductal adenocarcinoma. The level of metastatic disease were significantly reduced in 
all warfarin treated animals. We also confirmed the close relation between AXL and 
EMT, as epithelial markers were upregulated when AXL was inhibited. The cells 
migratory and colony forming capabilities were also impaired after AXL inhibition.  
In the population-based register study we observed an overall cancer protective 
association, with lowered incidence rate ratio of cancer in warfarin users compared to 
non-users. This was observed both for all-site cancer, and for the most prevalent 
cancer diagnoses in the material.  
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Altogether, our results emphasizes the importance of the receptor tyrosine kinase AXL 
in the development and progression of cancer. Warfarin-mediated AXL inhibition are 
shown to have a cancer protective effect, both in murine model systems and in 
population level studies. The results from this thesis suggest further investigations, to 
fully illuminate the potential use of warfarin in an anti-cancer setting.   
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The term cancer describes a diverse group of diseases. These diseases can present very 
differently, but share common features of uncontrolled cell division, and the ability of 
metastatic dissemination. The term malignant is used when cells in a tumor has the 
ability to invade either nearby, or distant tissues.1 Cancer is a major health problem 
throughout the world. In Norway, there were 32,592 new cases of cancer reported in 
2015. As shown in figure 1, the three most frequent cancer sites for men were prostate, 
lung and colon, and for women they were breast, colon and lung.  
 
Figure 1: The most frequent cancer types in Norway 2011-2015. Adapted from2 
In 2014, 10971 cancer deaths were reported, and death from cancer was the second 
most common cause of death after heart-diseases. For men, lung cancer (1198) and 
prostate cancer (1093) are the more frequent causes of cancer death, and lung (960), 




Figure 2: Age-standardized (Norwegian standard) mortality rates per 100 000 person-years for selected cancers in 
Norway, 2014. Adapted from2 
1.2 Pancreatic cancer 
 
Pancreatic cancer is the fourth leading cause of cancer death in Norway, with a 5-year 
relative survival of 6.4%.2 Pancreatic cancer is the 12th most frequent cancer worldwide, 
but the high overall mortality, with 330,000 deaths in 2012 makes it to the seventh most 
leading cause of cancer death.3 There are several risk factors for developing pancreatic 
cancer, with increasing age as the major one. The cancer form is rarely seen before the 
age of 40 years, and the risk is 40 times increased at the age of 80 years. Family members 
of patients with pancreatic adenocarcinoma has an approximately threefold risk of 
developing the disease, suggesting a genetic inheritance.4 Also increasing body mass 
index, new onset diabetes mellitus, chronic pancreatitis, and smoking are factors known 
to increase the risk.5 
The most common form for pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC), with over 85% of all pancreatic neoplasms being of this origin.4 These tumors 
are located in the head of pancreas in 65% of the cases, and tumors with this localization 
is normally presenting earlier than other localizations, mainly with symptoms as acute 
pancreatitis, jaundice and/or biliary obstruction.5 Several mutations are linked to the 
progression of PDAC. The most described ones are activation of the oncogene VI-KI-
RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS), followed by inactivation of 
several tumor suppressor genes, such as cyclin dependent kinase inhibitor 2A 
(CDKN2A),SMAD family member no 4( SMAD4)/Deleted in pancreatic cancer -4 (DPC4), 
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Tumor protein p53 (TP53) and Breast cancer 2 (BRCA2).4,6 In most cases, PDACs evolve 
through non-invasive precursor lesions, so-called pancreatic intraepithelial neoplasias 
(PanINs). These are microscopic lesions, (<5mm), and not detectable by non-invasive 
imaging. The PanINs are graded from 1 to 3 after level of cellular atypia. Low-grade 
PanINs (PanIN1) are increasingly common with increasing age. High-grade PanINs 
(PanIN3) are usually found together with invasive cancer.6 The genetic alterations 
associated with invasive cancer are also found in PanINs and the prevalence of these 
alterations will increase corresponding to the cytological and architectural atypia in the 
PanINs. KRAS gene mutations are normally one of the first alterations to be present in 
these lesions, and are increasingly frequent with the development of more advanced 
disease. At the stage of PDAC, nearly 100% of the tumors present with KRAS 
mutations.4,7 
1.2.1 Other pancreatic tumors 
 
Neuroendocrine tumors  
Pancreatic neuroendocrine tumors (PNET) are rare, representing 1-2% of all pancreatic 
tumors. They originate from pluripotent cells in the pancreatic ductal/acinar system. 
They could be secreting biologically active hormones, or they could be non-functional 
(60-90%). Hormone secreting tumors can give many different clinical syndromes, where 
hyperinsulinemia (insulin-secreting tumors), and Zollinger-Ellisons syndrome (gastrin-
secreting tumors) are the most common forms.8  The malignant potential of these 
tumors vary from slow-growing tumors with non-invasive growth, to invasive and 
metastatic tumors.9,10 
Acinar cell carcinoma 
Acinar cell carcinomas (ACCs) are rare neoplasms, accounting for 1-2% of all pancreatic 
tumors.11 These tumors produce high amounts of digestive enzymes, which can give 
symptoms as skin rashes and joint pain.12 The distinction between ACCs, and PNET can 




Cystic neoplasms of pancreas 
Malignant cystic tumors of pancreas represent 3-4% of pancreatic neoplasms and the 
most common forms are mucinous cystic neoplasms, serous cystic neoplasms and intra-
ductal papillary mucinous neoplasms (IPMN). Mucinous cystic neoplasms are the most 
frequent type, representing 40% of the cystic neoplasms. The prognosis is similar to 
PDAC, except patients with IPMN can present with pre-invasive lesions, which have a 
more favorable prognosis.5  
1.2.2 Staging of pancreatic cancer 
 
Pancreatic cancer is staged from 0 to IV regarding size, borders and affection of 
surrounding tissue and/or lymph node and distant metastases.6 The staging is based on 
the  Tumor, Node, Metastasis (TNM) classification of malignant tumors.13  
Pancreatic cancer is staged at the point of diagnosis, and the staging will be 
determinative for choice of treatment. 
Stage TNM Category Median survival 
0 Tis, N0, M0 Local or resectable 17-23 months 
IA T1, N0, M0 Local or resectable 17-23 months 
IB T2, N0, M0 Local or resectable 17-23 months 
IIA T3, N0, M0 Local or resectable 17-23 months 
IIB T1, N1, M0; T2, N1, M0;  T3, N1, M0 Local or resectable 17-23 months 
III T4, any N, M0 Locally advanced or unresectable 8-14 months 
IV Any T, any N, M1 Metastatic 4-6 months 
 
Table 1: Staging of pancreatic cancer. Adapted from6 
 
1.2.3 Treatment of pancreatic cancer 
 
The treatment opportunities in advanced stages are few, and are yet not very effective.6 
In the following section, the most common choices of treatment are described.   
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1.2.3.1 Surgery 
Surgery, with complete surgical resection of the tumor is considered to be the only way 
to cure the disease. Unfortunately, surgery is possible in only  ~10% of the patients.6,14 
Metastases at the time of diagnosis is an absolute contraindication for operation.15 Even 
after radical surgery, the majority of the patients have a poor prognosis due to 
recurrence of tumor, and metastatic development.5  
The methods used for surgical intervention, are pancreaticoduodenectomy (Whipples 
operation), distal resection of pancreas or total pancreatectomy. Operative mortality is 
low, and the procedure should be performed at centralized surgery wards, with 
preferably more than 15-20 pancreaticoduodenectomies per year. This is important to 
keep the complication rate as low as possible.6 
1.2.3.2 Chemotherapy 
Adjuvant treatment is given with the purpose to prevent, or delay, any recurrent 
disease. This treatment is given to patients after radical surgery with curative intention. 
The most used regimens are 5-fluorouracil and leucovorin, or gemcitabine, both for a 
period of 6 months. In some cases, neo-adjuvant chemotherapy is indicated, but this is 
still somewhat controversial, and is not yet recommended as standard treatment in 
Norway.16 Also FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) could 
have a potential in an adjuvant setting, and this is currently in clinical trials 
(NCT01526135).17  
In a palliative setting, FOLFIRINOX is first choice, when performance status is good. This 
gives an acceptable quality of life for most of the selected patients with relatively few 
side effects as long as the Eastern Cooperative Oncology Group (ECOG)-score is 0-1 
before start. In addition, albumin-bound paclitaxel (nab-paclitaxel) and gemcitabine, or 
gemcitabine and capecitabine could be an option for patients when FOLFIRINOX is 
considered too toxic. In addition, gemcitabine monotherapy is an alternative for 
patients when therapy that is more intensive is not feasible due to co-morbidities or 
other complications. If first line treatment gives stable disease for a period of time, it is 
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possible to continue with second line treatment after progression. Gemcitabine or FLOX 
(fluorouracil and oxaliplatin) can both be used as second line treatment in these 
settings.14,18,19  
1.2.3.3 New drugs in development 
Immunotherapy has shown encouraging results in early clinical trials, and different trials 
have different treatment approaches. Checkpoint inhibitors are promising, because of 
their ability to enhance the anti-tumor response of the immune system, and several 
clinical trials is currently ongoing in pancreatic cancer.  Programmed Death protein 1 
(PD1)/Programmed Death Ligand 1 (PD-L1) inhibitors or Cytotoxic T-lymphocyte 
associated protein 4 (CTLA-4) inhibitors are given alone or in combination with each 
other or already established treatment (NCT02311361, NCT02868632, NCT02866383, 
NCT02777710, NCT02734160).20 Therapeutic vaccines against pancreas cancer are also 
currently being tested, and furthermore, different monoclonal antibodies, cytokines 
and oncolytic virus therapies.21 
1.3 Tumor Biology 
 
Cancer development is a complex, multi-step process, normally developing over many 
years. The development of cancer requires changes, both regarding single cells and for 
their surroundings. Changes at cell level normally consists of mutations, deletions or up- 
or downregulation of regulatory proteins. An average tumor normally have 2-8 so-called 
driver gene mutations, providing the tumor with a growth advantage, in addition to 30-
60 less important mutations.22 Also microenvironmental changes and changes in how 
the environment responds to an atypical cell, is required in the development of a 
fulminant cancer.23 In 2000, Hanahan and Weinberg stated six hallmarks of cancer. (See 
figure 2)24 In 2011, two new emerging hallmarks were proposed.(figure 2).25
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Figure 2: Hallmarks of cancer. Adapted from25 
Sustained proliferative signaling is one of the most important steps in cancer 
development, and there are many ways to achieve this. Common for many of the 
different strategies are their influence on the cell cycle. During a normal cell cycle, 
several checkpoints are established to control the properties of the cell before the 
entering of a new cell cycle state.  In cancer, a common feature is that the cancer cell is 
continuously kept in an active proliferating state, without being withheld at the 
checkpoints and transferred to scenescense.26,27 Cancer cells can produce self-made 
growth factors giving rise to an autocrine stimulation of proliferation. The cancer cells 
can also stimulate neighboring cells in the tumor stroma to produce growth factors, or 
overexpress receptor proteins on their surface to make them hyper-sensitive in 
situations when limited access to growth factors otherwise could stop the signaling.28 In 
addition, ligand independent firing is possible due to structural changes in the receptors. 
Further, downstream pathways could be activated without receptor activation.25 The 
mentioned cellular changes have the potential of making growth factors constitutively 
active, which will stimulate the cell to increased proliferation.29 
A cancer cell will also deactivate mechanisms in the cell designed to negatively regulate 
cell proliferation. One example is the tumor suppressor gene TP53, which under normal 
conditions controls the internal cell machinery, and stops further cell cycle progression 
if the cell is under stress, or has developed genomic damage. Stressful cell conditions 
can be hypoxia or suboptimal glucose access, and this can activate TP53 and trigger 
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apoptosis.30 Many cancers have different mutations in TP53, mainly missense 
substitutions, and this will alter the proteins ability to suppress cell growth.31 An 
inactivating mutation of TP53 will lead to apoptosis evasion, and is seen in many human 
cancers. 31 
To be able to develop into macroscopic tumors, cancer cells will further need the ability 
to replicate unlimited. Telomeres are protecting the ends of chromosomes, but they are 
shortening in each division, until they no longer can protect the coding part of the DNA. 
Under normal circumstances, this will trigger a cell crisis, and subsequent cell death.25 
A majority of cancer cells expresses the enzyme telomerase reverse transcriptase 
(TERT), which will add segments to the telomeres located at the chromosome ends. This 
will prolong or even give the cells unlimited replication ability. Mutations in the 
promoter of the human TERT gene,  is one of the most common noncoding cancer 
related mutations, although common cancers like breast and prostate will normally not 
have this mutation.32 
It is also essential for every tumor to have access to a sufficient amount of oxygen and 
nutrients. To achieve this, it is necessary with an adequate vasculature to supply the 
needs of the developing tumor. During cancer development, preexisting vasculature 
continues to develop new blood vessels, despite being quiescent under normal 
conditions. This is often referred to as an angiogenic switch.33 Different tumors express 
different proangiogenic factors. Vascular endothelial Growth factor-A (VEGF-A) is the 
most widespread, but also fibroblast growth factor (FGF) and other members of the 
VEGF family are expressed in a cancer setting. Tumor blood vessels are different from 
normal vessels, being more irregular, dilated and with the occurrence of non-functional 
dead-ends.34 
The majority of the steps involved when a cell develops into a cancer cell, such as 
elevated levels of metabolic activity and cell division, is increasing the energy-needs of 
the cell. To meet the new requirements,  the developing tumor cells are dependent of 
changes in energy metabolism. The Warburg effect, first described by Otto Heinrich 
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Warburg in 1956, is a metabolic switch observed in cancer cells. In this process, the 
normal Adenosine triphosphate (ATP)-production via oxidative phosphorylation 
changes to ATP-production via glycolysis, also under normal oxygen levels.35,36 Glycolytic 
ATP-generation is quicker, but is using more glucose than oxidative phosphorylation, 
which demands a high level of glucose supply from the surroundings. The increased 
glucose uptake in the tumor tissue is exploited for diagnostic purposes, with the 
imaging-technique of [18F] fluorodeoxyglucose positron emission tomography (FDG-
PET).37 
Altogether, a series of events is required in the development from a normal cell to a 
cancer cell. The process could stop in any of these steps, and this will stop the cancer 
from developing further. Different treatment approaches is also able to target different 
of these steps, aiming to stop the process. As an example, bevacizumab is a monoclonal 
antibody targeting VEGF, preventing the development of a sufficient tumor 
vasculature.38 Also drugs that prevents cells for entering new cell cycles have been 
developed, targeting the key regulators of the cell cycle, the cyclin dependent kinases.39  
1.3.1 Mechanisms for metastases 
 
Metastases account for >90 % of cancer related deaths.40 An established metastatic 
tumor at a different and often distant site of the primary tumor is a result of a series of 
events, which involves local invasion, intravasation, circulative transportation, 
extravasation, micro-metastatic formation, and finally colonization and formation of a 
macroscopic metastasis. 41,42 The metastatic process can stop in either of these steps, 
and the outcome is depending on properties of the tumor cell, but also on responses 
from the microenvironment at the new site.42 It is shown that only approximately 0.02 
% of the cancer cells that enter circulation is developing into macroscopic metastases.43 
The potential of a cancer cells to metastasize is dependent on the degree of genomic 
instability in the cell. Cells with high grade of genomic instability will more easily acquire 
the alterations necessary to metastasize.44  It is known that the epithelial mesenchymal 
22 
 
transition (EMT) is a driver of the metastatic process, and this will be discussed further 
in section 1.4.2. 
Experiments have shown the metastatic potential of a tumor is closely related to 
increased resistance to apoptosis, which is considered as the initial step of the 
metastatic process.40 The cell detaches from surrounding cells and extracellular matrix 
(ECM), and at the same time take a more rounded shape due to degradation of the actin 
skeleton. In normal conditions, these processes would lead to apoptotic cell (AC) death, 
through either anoikis (apoptosis induced by cell detaching) or amporphosis (apoptosis 
induced by disrupted intracellular architecture).40 In a metastatic setting however, the 
abnormal cells will escape these processes, and continue to proliferate. It has been 
shown that overexpression of the anti-apoptotic protein B cell lymphoma 2 (BCL-2) 
increases the metastatic capacity of mammary epithelial cell, without affecting other 
important steps as primary tumor growth, cell motility or invasiveness.45 Also the 
metastatic steps of intravasation, circulation, extravasation and establishment in a new 
micro-environment are promoted by anti-apoptotic mechanisms.40  The steps of 
metastatic development are illustrated in Figure 3.  
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Figure 3: The pathogenesis of cancer metastasis. The process of metastasis can stop in any of these steps. Adapted 
from42 
It is known that certain tumor types will metastasize to different specific organs. This 
problem was addressed as early as in 1889 with Paget’s Seed and soil theory, where 
certain tumor cells (the seed) are hypothesized to  have specific preferences for a 
certain micro environment in specific organs (the soil), independently of the rate of 
blood flow in the different organs.46 A few years later, in the 1920s, another model of 
explanation were suggested.  At this point, James Ewing proposed the theory of a 
circulatory pattern between primary tumor and metastatic organs. According to this 
theory, the metastatic sites are passive receptors of tumor cells, and the preferred 
organs depend on the circulatory network between the primary and metastatic site. 
Later experiments have confirmed that both theories could be valid, as the number and 
localization of metastases could depend both on mechanical factors as blood supply and 
tumor cell delivery, and also microenvironmental factor where the local environment at 




To form a metastasis, the tumor cell has to survive in the new environment at the 
metastatic site. It is shown that AKT signaling is important in this matter, both when the 
tumor still is in circulation, but also in specific organs, as lung or bone marrow, to 
prevent the cell of undergoing apoptotic processes in the early phase of establishing a 
metastatic tumor.48 Once localized at the new site, the metastatic cells have the 
capability of establishing a metastatic niche, in terms of releasing soluble factors or 
micro-vesicles to make the new microenvironment more facilitated for tumor 
development.49 There is also hypothesized, although still debated, that tumor cells 
already at the primary site or in the circulation can secrete molecules to prepare the 
microenvironment at the site of metastasis, making a so-called pre-metastatic niche. 
This is in line with Paget’s seed and soil theory.48,50 It is proposed that modifications of 
the stroma includes increased levels of fibronectin and matrix metalloproteinases 
(MMPs), structural changes is ECM and recruitments of bone marrow derived cells to 
make the environment more favorable for adhesion of the cancer cells, and 
subsequently metastatic colonization.51,52 
1.4 Epithelial to Mesenchymal transition 
 
Epithelial to mesenchymal transition (EMT) is a process with cellular transformation 
from an epithelial to a mesenchymal phenotype. It is an important process in 
embryogenesis, which allows cells to migrate to different localizations during phases of 
development, both in morphogenesis and organogenesis.53,54 The embryonic form of 
EMT can be referred to as type 1 EMT. The EMT process is occurring also in adult tissue, 
both in normal processes such as wound healing and inflammation (Type 2), but also in 
pathological processes as such cancer, leading to cell invasion, dissemination, and 
development of therapeutic resistance (Type 3).55  Characteristics of the EMT process 
are loss of cell polarity and cell-cell interactions, modulations of the adhesion between 
cells and ECM, enhanced proteolytic activity, ECM degradation, increased cell motility 
and reorganization of the cytoskeleton.56,57 
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Epithelial cells have several features classifying them as epithelial. They have a well-
defined apical-basal polarity with a basal membrane and widespread cell-cell contacts, 
such as tight junctions, which allows communication between the cells. They have a 
characteristic cobble stone-like shape, and are non-motile. 58,59 Epithelial cadherin (E-
cadherin) is an important protein responsible for the formation of adherence junctions, 
by making protein clusters connected to actin microfilaments. This provides a strong 
control of the epithelial architecture.60 E-cadherin is considered the main marker for the 
epithelial phenotype, and in vitro, a correlation between the lack of E-cadherin and loss 
of an epithelial phenotype has been demonstrated.60,61 Other important cell-cell 
contacts are the tight junctions.  The Claudin protein family is the most important 
component of the tight junctions, followed by the protein occludin. Both Claudin and 
Occludin are commonly used as markers for an epithelial phenotype, and they are 
shown to be downregulated during the process of EMT.53,57,62 
The phenotype of mesenchymal cells are quite different from epithelial cells. The shape 
is more elongated and spindle-like, and they do not have the strict apical-basal polarity 
seen in epithelial cells. They also lack the cell-cell contacts, which are critical in the 
epithelial cell structure. Furthermore, mesenchymal cells have the ability to migrate as 
single cells, and display another set of proteins than the epithelial cells, such as the 
mesenchymal markers Vimentin and N-cadherin.59 In cancer, the levels of proteins that 
are characteristic of mesenchymal cells, and simultaneously loss of epithelial markers, 
correlates with evidence of tumor progression and poor prognosis.63 Typically, the cells 
expressing mesenchymal markers are seen in the invasive front of primary tumors, and 
are most likely the cells that first will start disseminating.55,60,64 
1.4.1 Activation of EMT 
 
The EMT program is activated by developmental transcriptional regulators. The most 
important of these are TWIST, Zinc finger E-box binding homeobox 1 and 2 (ZEB1 and 
ZEB2), and two members of the snail superfamily of transcription factors, SNAIL (SNAI1) 
and SLUG (SNAI2).65,66 These transcription factors will change the gene expression 
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profile, by repression of the genes encoding for the epithelial proteins (e.g. E-cadherin 
and β-catenin) and induction of increased expression of mesenchymal proteins, such as 
Vimentin and N-cadherin. As an example, it is shown that SNAIL and ZEB bind to, and 
subsequently repress the activity of the E-cadherin promoter, and by that regulating the 
expression of E-cadherin.67 SNAIL and ZEB are also contributing to destabilization of 
epithelial cellular polarity, which is a key feature of epithelial phenotype. By inducing 
expression of different metalloproteases that will degrade the basal membrane, they 
stimulate cellular instability and invasion.68 Also expression of Claudins, which are 
important for tight junctions are downregulated by SNAIL. This is thought to be via the 
lysine specific demethylase 1 (LSD1).69 There is also evidence for a positive feedback 
loop in this system. The metalloproteinase MMP3 will increase levels of reactive oxygen 
species (ROS) in the system, and that will again stimulate the expression of SNAIL.70 
Furthermore, it is shown that especially expression of SNAIL is closely related to 
signaling of transforming growth factor β (TGF-β).71 This is relevant, both during normal 
development, and in cancer.53,71 TGF-β has a two-sided role in the development of 
cancer. In many conditions, it is an important suppressor of epithelial cell proliferation 
and subsequently primary tumorigenesis. It will nevertheless serve as a positive 
regulator of tumor development in other conditions.72 During tumor progression, there 
is evidence that the tumor cells will lose their normal TGF- β- related growth inhibition, 
due to mutational changes. This will lead to increased growth, followed by more 
mutations, and subsequently cancer progression.73 In a different pathway, there is 
evidence that the signaling protein Ras will be activated, and this will enhance the 
effects of TGF- β that promotes tumor progression, and metastatic development.73 TGF- 
β also have the potential to activate the phosphatidylinositol 3OH kinase (PI3K) pathway 
with its downstream target AKT, which will lead to EMT –induction.74 WNT signaling also 
have the potential of stimulating EMT. This large family of proteins are involved in 
several cancer types. Activation of the WNT pathway will phosphorylate Glycogen 
synthase kinase 3 beta, (GSK3β), a tumor repressor, and this will via β-catenin activate 
transcription of SNAIL, and stimulate the EMT process.74  
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1.4.2 EMT control 
 
The process of EMT can be controlled by different factors. MicroRNAs (miR) are 
important in this respect. MiRs are small pieces of RNA (approximately 22 NT) which can 
bind to target mRNA and influence the translation. Especially, miR-200 is associated with 
EMT by regulating expression of ZEB.75,76 There is also evidence of down-regulation of 
miR-200 family members in several human cancers.77-79 Also SNAIL-dependent EMT can 
be regulated by miR, most commonly by the miR-34 family.80,81  Both the miR-200 family 
and the miR-34 family are controlled by the tumor suppressor TP53.81,82 TP53 will bind 
to the promoter of miRNA-200, and stimulate its expression. Loss of TP53 in breast 
cancer will give less expression of miRNA-200, increased activation of the EMT-program 
and development of cells with stem-cells properties.82 
1.4.3 EMT and Cancer 
 
In cancer development, EMT is thought to have an important role as a facilitator for 
dissemination and metastatic spread.  This type of EMT is often referred to as type 3 
EMT.55 The process of EMT  in cancer is strongly dependent of the tumor 
microenvironment, and micro-environmental factors will in many cases decide if a cell 
has the potential to undergo EMT and then metastasize.83 The loss of E-cadherin during 
EMT is inversely correlated to cancer grade and patient survival, and E-cadherin 
downregulation is associated with increased cell growth.60 A number of different growth 
factors will contribute to EMT in cancer, and the growth factor signaling will vary in 
different cell types. Examples of growth factors that can induce EMT are epidermal 
growth factors (EGFs), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), 
insulin-like growth factors (IGFs) and as before mentioned, TGF-β.54 Also activated Ras/ 
mitogen activated protein kinases (MAPK), Src kinase and PI3K-signaling are shown to 
be inducers of the EMT program.54 These pathways are associated with important 
hallmarks of cancer, such as ability to regulate cell cycle, sustained proliferation, and 
also the properties of evading growth suppression and apoptosis.25 Other tumor-related 
factors can also trigger EMT in cancer. Intra-tumoral hypoxia could trigger the 
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expression of SNAIL, and subsequently the process of EMT. Thus, this is an important 
factor in tumor development, together with acidic conditions, inflammation and low 
blood glucose.54,84,62 
The role of EMT in cancer progression is still not fully understood. It is proven that EMT 
is not required for establishment of metastases, despite being very important for the 
invasive development.57 Furthermore, cells with different EMT status could be present 
within the same tumor. It is hypothesized that there is an EMT gradient in different 
segments of the tumor, and that the cells goes through different states of intermediate 
EMT levels, where they gradually lose their epithelial phenotype.57,85 One theory is that 
a malignant tumor has an invasive front, where the cells have undergone EMT and have 
mesenchymal properties, whereas the main part of the tumor still largely is epithelial.57  
Both in embryogenesis, and in cancer development, EMT is a transient phenomenon. 
After cell dissemination and spread to distant sites, the cells will go through the opposite 
process, mesenchymal to epithelial transition (MET) in order to establish macro-
metastases at the new localization.60,62 In metastases, the cancer cells exhibit 
histopathological similar traits as the cells in the primary tumor, lacking the 
mesenchymal phenotype, supporting the theory of the process of MET.55 It is proposed 
that this is because the microenvironment in the new localizations will not provide the 
EMT stimulating signals present at the primary location, leading to a reversal of the 
process.86  
EMT is important also in other steps in the malignant development, such as resistance 
to cell death. TGF- β can induce EMT in mammary cells, and at the same time inhibit 
apoptosis. It is also shown that EMT induction can give rise to a phenotype with 
resistance of cell senescence induced by oncogenes.87 
1.4.3.1 EMT and Cancer stem cells 
The EMT program has in several studies also been linked to the development of cancer 
stem cells (CSCs). A subset of the cells undergoing EMT is exhibiting stem-like properties, 
or being in a condition, just ready to enter the stem cell state.88-90 The hypothesis is that 
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these cells will exhibit some of the same traits as normal stem cells, such as the ability 
to self-renew and serve as progenitors for cell clones with adaptive characteristics.91 
There is not consistency about the origin of cancer cells with stem-like traits, and 
different theories have been suggested. Dedifferentiation of the a cancer cell together 
with EMT is one of the proposed mechanisms, together with the hypothesis of 
malignant transformation of a normal stem cell, and induction of pluripotent cancer 
cells. In the invasive front of tumors there is evidence for expression of both stemness-
associated genes, and EMT-related genes, supporting the theory of a dedifferentiation 
of a subpopulation of cancer cells together with EMT.92 It is shown that both the 
transcription factors SNAIL and TWIST stimulate the acquisition of stem cell properties 
in cancer cells. 87 Investigations of cells that have undergone EMT and exhibit 
mesenchymal markers show that a significant proportion of these cells will express cell 
surface markers compatible with stem cell traits, with a CD44high/CD24 low ratio.88  
1.4.3.2 EMT and drug resistance 
It has been shown that the EMT-related transcription factor SNAIL can induce resistance 
to both chemotherapy and immunotherapy, and also immunosuppression. 
Furthermore, TWIST is capable of inducing resistance to senescence.87,93 Investigations 
of cell lines resistant to chemotherapy revealed that these cells present with a 
mesenchymal phenotype, and express markers of EMT.94,95 In acquired resistance, 
evidence shows that the process of EMT gives rise to more mesenchymal cells with 
chemo-refractory abilities and stem cell like features.96 Also de novo resistance is related 
to EMT. In treatment of lung cancer with EGFR kinase inhibitors, sensitive tumors have 
elevated E-cadherin levels, while drug resistant cells have properties that are more 
mesenchymal.97  
1.5 Receptor tyrosine kinases 
 
Receptor tyrosine kinases (RTKs) are a group of transmembrane proteins, functioning 
as cell surface receptors and regulators of many cellular processes. In the human 
genome there are 58 RTKs, separated in 20 subfamilies.98 The molecular structure of all 
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the RTKs are similar, containing an extracellular ligand-binding domain, and an 
intracellular tyrosine kinase region, separated by a transmembrane helix. RTKs are 
normally activated by ligand binding, followed by receptor dimerization and activation 
of an intracellular kinase domain.98 Overexpression of RTKs, commonly because of gene 
amplification, is closely related to many human cancers.99 Figure 4 gives an overview of 
human RTKs. 
 
Figure 4: Human receptor tyrosine kinases. Adapted from99 
1.5.1 AXL receptor tyrosine kinase 
 
AXL is a RTK and a member of the TAM (TYRO, AXL, MER), family of RTKs which is a group 
of transmembrane RTKs. AXL is located at chromosome 19, and is encoded by 20 exons. 
The receptor is approximately 140 kDa in a fully glycosylated state.100,101 The name AXL 
is from the Greek “anexelekto” which means uncontrolled.100 AXL was first discovered 
in Chronic myelogenous leukemia, as an unidentified transforming gene.102 In normal 
tissues, AXL has a ubiquitously distribution. Detectable levels of AXL are found in 
endothelial cells, heart, kidney, liver, monocytes/macrophages, platelets, skeletal 
muscle, and testis. Also in the normal brain, there is evidence of AXL, most notably in 
cerebellum and hippocampus.103  
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1.5.1.2 AXL structure 
The structure of AXL is similar to other RTKs. AXL consists of an extracellular domain (N-
terminal), containing two fibronectin type III domains, and two immunoglobulin (IG)-like 
domains.100,104 The intracellular tyrosine kinase domain (C-terminal) contains an unusual 
KWIAIE amino acid sequence, which is unique for the TAM family of RTKs. This sequence 
is similar, but different to the consensus sequence for all the tyrosine kinases.100 The 
intracellular domain has an ATP-binding site, which catalyzes receptor auto-
phosphorylation and serves as a docking site for cytoplasmic signaling proteins 
containing domains for protein tyrosine binding and src-homology-2.105 This structure 
is common for all the TAM RTKs. Figure 5 shows the structure of AXL and its ligand GAS6. 
 
 
Figure 5: Structure of the receptor tyrosine kinase AXL and its ligand GAS6. Adapted from106 
1.5.1.3 AXL ligand 
AXL is activated by its ligand Growth arrest specific 6 (GAS6) which was first identified 
in 1995.107 GAS6 is a vitamin-K dependent protein, containing a gamma-glutamic acid 
residue (Gla) –rich domain at the N-terminal. The Gla-domain is under normal 
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conditions carboxylated from glutamate to gamma-carboxyglutamate prior to receptor 
binding. This vitamin-K dependent process is necessary for GAS6-mediated activation of 
AXL.108-110 In addition to the Gla-domain, GAS6 also consists of four EGF-like repeats and 
a sex hormone binding globulin at the C-terminal, which includes two laminin G-like 
domains.111  Structural studies have shown that there are two binding sites between 
AXL and GAS6, one major contact between  LG1GAS6 and IG1AXL and one minor contact 
between LG1GAS6 and IG2AXL. Both the points of contact are required for AXL 
activation.112  
1.5.1.4 AXL activation 
After binding, AXL and GAS6 are creating a strong 1:1 GAS6:AXL complex, followed by a 
dimerization of two 1:1 GAS6:AXL complexes.112 After gamma-carboxylation, the Gla-
domain of GAS6 will bind to phosphatidylserine (PtdSer) on neighboring cells in a 
calcium-dependent process. Many cell types throughout the body are expressing 
PtdSer. In most conditions, PtdSer is located at the inner leaflet of the plasma 
membrane, but activated platelets and ACs are presenting the PtdSer on the outside.113 
The interaction between the Gla-domain and the PtdSer on neighboring cells is 
optimizing receptor activation.110 There are conflicting reports regarding the possibility 
of AXL activation without simultaneously binding of PtdSer. The evidence is consistent 
in the findings of that the PtdSer binding is not essential for the binding of GAS6 to the 
receptor, but the presence of PtdSer is thought to increase the affinity.114 A study from 
2014 argues that the gamma carboxylation of the Gla-domain is essential for receptor 
activation, but there is no need of following binding to PtdSer for receptor signaling.115 
Another report from the same year argues that AXL signaling depends both on the 
carboxylation of GAS6 and subsequent binding of PtdSer.110 On the contrary, a more 
recent report demonstrates a possibility of receptor activation without gamma 
carboxylated Gla domain, and subsequently no binding to PtdSer but the activation will 
then be of weaker character.116 Figure 6 illustrates the GAS6-mediated activation of AXL.    




Figure 6: GAS6:AXL activation. Illustrates that AXL is activated of GAS6 and not Pros1, and that AXL is dependent of 
carboxylated Gla-domain of GAS6 binding to PtdSer on neighboring cells. Adapted from Lew et al110  
There is also evidence that ligand-independent processes can activate AXL. This can be 
through interaction of two monomers on neighboring cells, causing cell aggregation, 
ligand independent dimerization and heterotypic receptor-dimerization with a non-
TAM receptor.111,117 Ligand-independent activation of AXL is related to AXL 
overexpression, and is therefore more likely to occur under pathological conditions, 
such as cancer.118,119 Especially the homophilic binding of the extracellular domains on 
neighboring cells can lead to cell aggregation, and is associated with cancer, when the 






Figure 7: Mechanisms of AXL receptor activation/inactivation. A: Ligand induced activation. High affinity 1:1 
GAS6:AXL complex followed by a dimerization of two GAS6:AXL complexes. B: Hemophilic binding of extracellular 
domain of AXL expressed on neighboring cells can lead to cell aggregation especially when AXL is overexpressed. 
C: Ligand independent hemophilic dimerization of AXL and auto-phosphorylation in response to ROS. D: Proteolytic 
cleavage of AXL to form soluble AXL (sAXL). Adapted from118  
After the dimerization of the complexes, there will be a subsequent auto-
phosphorylation of the intracellular kinase domain of AXL. There are several intracellular 
tyrosine residues which can be phosphorylated, the most described sites are Y779, Y821 
and Y866, all located in the C-terminal kinase domain.118,121 
After activation of the GAS6:AXL complex, there is a cleavage of the extracellular domain 
from the cell surfaces, a process conducted by proteases.122 There is evidence that 
elevated soluble AXL (sAXL) in blood can be a marker of different conditions of variable 
character. For example, sAXL is suggested as a potential biomarker for inflammation, 
and early stage hepatocellular carcinoma.123,124 
1.5.1.5 Downstream events of AXL 
The activation of AXL is linked to different intracellular signaling cascades, where several 
also are related to tumor development. The downstream signaling is thought to be 
similar to other RTKs, and different pathways are activated at different time points, 
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determined by tissue type, cell type and extracellular environment.101 The PI3K- 
pathway, with the downstream targets AKT and S6K, and also the phosphorylation of 
nuclear factor-κB (NF-κB) is one of the major downstream pathways of AXL activation. 
PI3K is an intracellular kinase and the key component of a pathway mediating several 
cellular responses related to cancer development, such as growth, motility and 
survival.125 It is evidenced that the p85 (α and β) subunit of PI3K is interacting with a 
multi-substrate docking site at the tyrosine 821 on AXL.121,126 Activation of PI3K and 
subsequently NF-κB, will lead to increased expression of anti-apoptotic proteins such as 
B-cell lymphoma 2 (BCL-2) and B-cell lymphoma extra-large (BCL-XL), and inhibition of 
pro-apoptotic proteins like caspase 3.103 Furthermore, AKT will phosphorylate the pro-
apoptotic BAD, which subsequently will not be able to interact with BCL-XL and BCL-2. 
This will lead to decreased apoptosis, and increased cell survival.127 It has been shown 
in Gonadotropin releasing hormone -neurons that PI3K can mediate activation of p38, 
which in turn will lead to phosphorylation of Heat-shock protein 25. This is a regulator 
of actin modelling, and its activation will regulate remodeling of actin, which will favor 
increased migration.128 Also p-21-activated kinases -1 (PAK1) is known to be activated 
through the PI3K/AKT pathway. PAK1 stimulates cell invasion when activated.129 
Another downstream target for AKT is GSK3. This protein has been shown to mediate 
several oncogenic traits, such as cell survival, proliferation and cell cycle progression.130 
Overall, AXL-mediated activation of the PI3K-pathway is linked to increased cell survival, 
proliferation and cell migration. 
The MAPK/extracellular signal regulated kinases (ERK) signal transduction cascade is 
also initiated upon AXL phosphorylation. The tyrosine kinase domain of AXL will after 
auto-phosphorylation bind to the intracellular Grb2 protein, which then will activate the 
MAPK/ERK pathway.121 This pathway is often linked to AXL-mediated proliferation.103,131 
This GAS6-mediated induction of ERK is both in strength and duration comparable to 
what is seen in response to more well-described growth factors, such as EGF and 
platelet derived growth factor.132 The growth-stimulating effect of GAS6 is additive to 
36 
 
the effect of EGF, which suggests that GAS6 utilizes other pathways than those utilized 
by EGF.126,132 
AXL signaling is heavily involved in the human immune system. Together with the other 
TAM receptors, the GAS6:AXL complex will protect innate immune cells such as 
macrophages, dendritic cells and natural killer cells (NK cells), from apoptosis. Via the 
type 1 interferon receptor (IFNAR), GAS6:AXL will initiate phosphorylation of the 
transcription factor STAT 1, a member of the Signal transducers and activators of 
transcription family of transcription factors, and subsequently the expression of 
suppressor of cytokine signaling  1 and 3 (SOCS 1 and 3), which are inhibitors of 
cytoplasmic cytokines. SOCS 1 and 3 will also inhibit Toll-like receptors (TLR) on dendritic 
cells, and by this inhibit their inflammatory response to pathogens. These pathways are 
very important for controlling inflammatory responses.118,133 Also STAT3 is linked to 
GAS6:AXL. STAT 3, as STAT1, belongs to the STAT family of transcription factors, and is 
persistently activated in many cancers. STAT 3 is known to be an important mediator of 
the oncogenic effects of EGF.134 In head and neck-cancer and colorectal cancer, it is 
shown that inhibition of AXL will lead to reduced phosphorylation of STAT3.135,136  
Furthermore, there is shown a relationship between AXL and the cytokine interferon-α 
(IFN-α).104 Secretion of IFN-α will upregulate AXL in macrophages, which in turn will lead 
to increased TWIST expression and reduced tumor necrosis factor α (TNFα) production. 
TNFα is a strong inflammatory cytokine, and reduced production will give a weaker 
inflammatory response.137  
The downstream events of AXL is illustrated in Figure 8. 
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Figure 8: Downstream events of AXL.  This figure show the downstream events after AXL activation. The 
boxes show the final outcome after the intracellular processes are activated.  
1.5.1.6 AXL regulation 
Some intracellular proteins have the ability to inhibit and regulate the activity of AXL. C1 
domain containing phosphatase and TENsin homologue (C1-TEN) is a protein that will 
bind to the intracellular compartment of AXL. This will negatively regulate AXL signaling 
through PI3K/AKT. The detailed mechanisms behind this inhibition are still unclear. 
When overexpressed, C1-TEN will inhibit the cells ability to proliferate and migrate.138 
There is also evidenced that soluble forms of AXL (sAXL) are circulating in plasma, and 
will, by binding to GAS6, inhibit receptor activation.115,139 As other RTKs, AXL is regulated 
by a mono-ubiquitination signal, which leads to endosomal internalization and 
degradation by lysosomes. The regulating ligase for AXL internalization is Casitas B-
lineage Lymphoma-c (c-Cbl).101,140. In kidney cancer it is shown that cells with low levels 
of VHL have increased AXL expression, due to binding of hypoxia-inducible transcription 
factor 1 and 2 (HIF-1 and HIF-2) to the AXL promoter.141,142 Myeloid Zinc finger 1 is 
another protein that is regulating AXL expression by binding to the promoter. This will 
activate the promoter, and increases the expression of AXL.143 
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There is also evidence for AXL regulation at the mRNA level. Two miRs are identified 
(miR-34a and miR-199a) which binds to the 3’UTR of AXL, having an inhibitory effect on 
AXL protein levels.144,145 A recent study in ovarian cancer shows that expression of miR-
34a will lead to decreased AXL expression followed by significantly inhibited cell 
migration.146 Similar findings have been shown in prostate cancer where expression of 
miR-34a leads to downregulation of AXL, and induced apoptosis, and growth 
inhibition.147 In osteosarcoma it is shown that miR-199a-3p will downregulate the 
expression of the AXL gene, and this will inhibit progression of the disease. Also, low 
levels of miR-199a-3p significantly correlates with recurrence of lung metastases, and 
low levels of miR-199a are a predictor of poor prognosis in osteosarcoma.148  Specificity 
protein 1 and 3 (Sp1/Sp3) transcription factors are also regulators of AXL expression by 
binding to Sp motifs upstream for the AXL promoter, and by that driving AXL expression. 
In low AXL-expressing cells, these motifs are methylated which will restrict AXL 
transcription. This is in contrast to high AXL-expressing cells, where there is evidence for 
a hypo-methylation of the Sp motifs. Experiments with demethylation of these areas in 
low AXL-expressing cells, lead to increased AXL expression.149 
1.5.1.7 AXL in normal physiology 
In the normal physiology, the expression of AXL is widespread throughout the body, 
although mainly in the mature immune, nervous, reproductive and vascular systems.150 
Still, none of the TAM receptors is essential for embryonic development, as TAM -/- are 
viable after birth.114  
Hemostasis 
AXL-expression on platelets will mediate thrombogenesis and platelet stabilization.151 
The receptor will be activated by PtdSer on aggregating platelets, and simultaneous 
release of GAS6 from granules in the platelets. This process is contributing to stabilizing 
the clot formation. GAS6 -/- mice show signs of impaired platelet aggregation, with 
prolonged bleeding time.114,152 TAM RTKs are also involved in other parts of the vascular 
homeostasis, such as reestablishment of the endothelial barrier function after vascular 
damage, and also by promoting survival of endothelial cells.153 Furthermore, AXL is 
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known to play a role in neovascularization, and it is shown that AXL is important for 
VEGF-A induced endothelial cell migration and subsequent formation of new blood 
vessels. This is effectuated through the downstream PI3K/AKT pathway.154  
Mediation of phagocytosis of apoptotic cells  
In the process of phagocytosis, the TAM ligands GAS6 and Pros1 binds to PtdSer on ACs, 
and serves as a bridging molecule between the AC and a TAM-receptor on a neighboring 
phagocyte. After activation of the TAM-receptor, this linking of the cells will push the 
apoptotic process forward.104 This is an important step in normal physiology, and 
necessary to prevent a state of continuous inflammation.153 In AXL knockout (KO) 
animals the consequences is shown to be severe, with an accumulation of dead ACs. 
Especially regarding sperm production and in retina, this is important, leaving the AXL 
KO animals blind and sterile.113 
Immunology 
All the TAM receptors, have an important role in the inhibition of the innate immune 
system.114  The receptors functions as a safety-system to prevent prolonged and over-
intense immune reactions and will promote tissue-repair after inflammatory responses. 
Dendritic cells have medium AXL expression at steady state, but the expression will be 
upregulated following pathogen invasion, which gives activation of TLR and further by 
type 1 IFN. This will contribute to the termination of the immune response after the 
specific pathogen reaction.133 Situations with low AXL will always present with chronic 
inflammation and a prolonged immune reaction. AXL KO mice have severe autoimmune 
disease in a clinical pattern similar of systemic lupus erythematosus or rheumatoid 
arthritis.155 When a virus enters the human organism, it is possible that AXL activation 
dampens the immune response, and thereby making it easier for the virus to escape the 
immune reaction. Many viruses have PtdSer on their external surface, and will by that 
activate AXL, and enter the cell. Infections like Zika virus, and also Ebola and West Nile 
virus has been coupled to AXL as a receptor for cell entrance.156 
40 
 
1.5.1.8 AXL and EMT 
AXL is known to be closely related to the EMT process.  Over-expression of EMT-related 
transcription factors, such as SLUG, SNAIL, TWIST and ZEB2 is linked to up-regulation of 
AXL.65 AXL up-regulation will additionally have a positive feedback on the transcription 
factors, leading to sustained expression of SLUG, SNAIL and TWIST.65,157 There is also a 
tight connection between expression of EMT-related proteins and AXL. An example of 
this is the mesenchymal protein Vimentin. This is a protein is an important regulator of 
mesenchymal cell migration, and a marker of EMT. The level of AXL is closely related to 
the level of Vimentin, and increased expression of both proteins will enhance the cancer 
cells migratory capacity.158 There is also evidence for a relationship between AXL up-
regulation and acquisition of drug resistance and an EMT phenotype. This is described 
in several cancers, such as lung cancer, breast cancer and chronic myeloid leukemia 
(CML).159-162 Furthermore, AXL expression is shown to be enhanced in breast cancer 
metastases relative to the primary tumor (investigated for matched samples). These 
findings strongly indicate that AXL is associated with epithelial plasticity and has a role 
in malignant progression and metastatic development.65  
1.5.1.9 AXL and cancer 
AXL is associated with many different cancers. It was first described in Chronic myeloid 
leukemia (CML) in 1988. In the beginning, it was described as an unidentified 
transforming gene.102,163 Activating mutations or amplifications associated with AXL are 
rare, rather up-regulation and increased ligand-induced activation is associated with 
cancer.100,164  In the recent years, there have been many reports of AXL up-regulation in 
several different cancer types. (Table 1). It is believed that the upregulation of AXL is 
induced by hypoxia in the tumor environment, which is a common feature of most solid 
tumors. Hypoxic conditions will stimulate HIF-1 and HIF-2 to express several genes as 
response to this, amongst these, AXL.142 Overexpression of AXL has several implications. 
It is related to poorer prognosis65,165,166, development of drug resistance159,161,167 and  
increased invasiveness.158 Malignancies related to AXL-upregulation, and the 
correlation with poor prognosis are summarized in Table 2. 
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Abbreviations: HCC: Hepato-cellular carcinoma, AML: Acute myeloid leukemia, CLL: Chronic lymphatic leukemia, 
CML: Chronic myeloid leukemia, SCLC: Small cell lung carcinoma, NSCLC: Non small cell lung carcinoma, RCC: Renal 
cell carcinoma. 
Table 2: AXL upregulation and correlation with prognosis. Adapted from 271 





Independent prognostic factor 
Astrocytic brain tumors 168-173 169,171,172 169 169 
Breast cancer 65,174-185 65,176-183,186 65,182,183,185 65 
Gallbladder cancer 187 187 187  
GI cancers 
Colon cancer 136,143,144,188-191 136,190,191 136,191 191 
Esophageal cancer 167,192-194 167,193,194 193,194  
Gastric cancer 195,196 195,196   
Gynecological cancers: 
Ovarian cancer 197-202 197-202 197,200,202 197 
 Uterine cancer 203-205 203-205 205  
Head and neck cancer 206-212 135,207,210-212 135,207,210,212 210,212 
Liver - HCC 213-217 214,217 214,217 214,217 
Leukemias: 
AML 166,218-220 166,218-220 166,218 166,218 
CLL 221-223 221-223   
CML 100,162,220,224 100,220   
Lung cancer: 
SCLC 225    
NSCLC 144,159,165,188,226-
234
159,165,231-234 230-232,234  
Malignant melanoma 235-238 238   
Mesothelioma 239-241   239 
Pancreatic cancer 109,242-244 242-244 242-244 242 
Sarcomas: 
Ewing Sarcoma  245 245  
Kaposis sarcoma 246 246   
Liposarcoma 247,248 247,248 247 247 
Osteosarcoma 249-251 249 249 249 
Undifferentiated     pleomorphic sarcoma 252 252 252  
Skin SCC 253,254 253,254   
Thyroid cancer 255-258 255,256,258   
Urological cancers: 
Bladder cancer 259-261  259  
Prostate cancer 262-265 263,265   
RCC 142,266-270 266-270 142,268 268 
42 
 
Invasion and metastasis 
Overexpression of AXL is thought to be more related to metastatic dissemination and 
poor overall survival than primary tumor growth.188,244 These observations correspond 
to the receptors close relation to EMT.  AXL will enhance invasiveness in many cancers, 
which corresponds to the association to metastatic development. The AXL-related 
PI3K/AKT activation has in breast, gastric and ovarian cancer been shown to enhance 
tumor cell invasion, via the NF-κB pathway.65,195,201. In hepatic carcinoma, AXL 
downregulation will lead to reduced expression and less activity in the PI3K/AKT 
pathway.216 PAK1 is known to be activated through the PI3K/AKT pathway, and PAK1 
stimulates cell invasion when activated.129 Inhibition of the PI3K/AKT pathway and 
subsequently PAK1 were shown to strongly reduce cell invasion ability.216 The E3 
ubiquitin ligase Casitas B-lineage lymphoma-b (Cbl-b) is) is activating Natural Killer cells 
(NK-cells). By inhibiting this ligase, the NK-cells will be triggered to reject metastatic 
tumors. AXL, together with the rest of the TAM family, is shown to be substrate for Cbl-
b, so by AXL inhibition, the activity of the ligase is inhibited, and the NK-cells will have 
an inhibitory effect of metastasis formation.272 
Cell survival 
Overexpression of AXL in tumor cells is in many conditions linked to increased cell 
survival. It is reported in different cancers that increased AXL expression leads to 
prevention of apoptosis, and subsequently increased survival. A work in breast cancer 
reports that elevated estrogen levels stimulate increased AXL expression and reduced 
levels of apoptosis.176 Also in osteosarcoma there is shown a strong relationship 
between increased AXL expression and protection from apoptosis. 251 Similar reports is 
seen in astrocytoma170, chronic lymphatic leukemia (CLL)222 and ocular melanoma237. 
Some of the anti-apoptotic potential of AXL, goes through the PI3K pathway.  Activation 
of PI3K and subsequently NF-κB, will lead to increased expression of anti-apoptotic 
proteins such as Bcl-2 and Bcl-XL, and inhibition of pro-apoptotic proteins like caspase 
3. In addition, the inhibitory interaction between BAD and Bcl-2 and Bcl-XL will be 
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blocked due to AKT-mediated phosphorylation of BAD. The total effect will be 
prevention of apoptosis and increased cell survival.103,127 
Angiogenesis 
Furthermore, there is strong evidence supporting AXL having a role in 
angiogenesis.273,274 In the normal cellular environment, AXL is involved with repair of 
vascular injury.275 Studies have shown that overexpression of AXL in cancer is present 
not only in the tumor cells, but also in surrounding vascular cells.169,233 Vascular smooth 
muscle cells (VSMC) express GAS6, and exogenous application of GAS6 will stimulate 
proliferation and mobility of VSMC.276  There is also evidence that AXL knockdown in 
endothelial cells (HUVEC) will impair tube formation, and that AXL is an important driver 
of proliferation of HUVEC cells.273 Furthermore, it is shown that AXL will influence 
angiogenesis through modulation of signaling, via angiopoietin/Tie2w and Dickkopf 
related protein 3 (DKK3) pathways. These proteins are known regulators of 
angiogenesis. In addition, combination of AXL knockdown and anti-VEGF therapy 
resulted in enhanced inhibition of tube formation compared to anti-VEGF therapy 
alone.188 Furthermore, Ruan et al show that AXL is essential for the VEGF-dependent 
activation of PI3K/AKT, supporting the evidence of AXL having important implications in 
angiogenesis.154 In vivo mouse studies have further shown a strong relationship 
between AXL and angiogenesis, and suggest that AXL inhibition will suppress formation 
of new blood vessels.157,273  
Tumor microenvironment 
AXL can also regulate factors in the tumor microenvironment. Malignant tumors have 
the ability of invading tumor-surrounding tissues. A crucial trait to achieve this is the 
capacity of producing matrix-degrading enzymes. MMPs are important enzymes 
regarding this. MMP-9 is a type IV collagenase, which degrades type IV collagen, an 
important structure in the basement membrane and ECM.277 It is shown that AXL 
enhances the expression of MMP-9, by regulating the promoter activity through the 
MAP kinase kinase MEK/ERK pathway.278. In the environment of a tumor, the conditions 
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are often hypoxic compared to the surrounding tissues. Hypoxia will increase the 
expression of HIF1α which will then promote increased AXL transcription.142 
1.5.1.10 AXL and drug resistance 
AXL is a facilitator for acquisition of drug resistance in many cancers. The mechanisms 
for this are not fully elucidated, but it is shown that AXL is significantly overexpressed in 
therapy resistant cancers compared to tumors in other stages.279 Especially in breast 
and lung cancer, this is thoroughly described.159,161,227,280 It is known that increased 
expression of RTKs is a compensatory reaction to therapy-induced inhibition of a specific 
signaling pathway. For AXL, this mechanism has been shown for both antimitotic drugs, 
and also targeted agents.281 In lung cancer with a situation of AXL overexpression, AXL 
will dimerize with EGFR, and by that activate downstream effects leading to limited 
sensitivity for anti-EGFR therapy and acquired resistance for RTK inhibitors.206 In head 
and neck cancer there is evidence that AXL over-expression will give inhibition of the 
signaling of c-ABL/p73, and subsequently reduced response to DNA-damage and 
decreased levels of  apoptosis, which in turn will give resistance against DNA-damaging 
drugs such as cisplatin.167 Also in malignant melanoma, AXL is important in developing 
resistance to MAPK inhibitors in B-Raf proto-oncogene serine/threonine kinase (BRAF) 
-mutant melanomas, and targeted AXL-inhibition increases the effect of treatment with  
BRAF-inhibitors when given together.282  
1.5.1.11 AXL and Immunotherapy 
In normal physiology, it is known that AXL is important in dampening the immune 
system, preventing immune overreactions and auto-immunity.104 In a cancer setting, 
with AXL overexpression, this is important, because AXL would facilitate for the tumor 
cell to survive attacks from the immune system.283  AXL-inhibition will activate the 
immune system in several manners. For example, NK-cells will be stimulated to anti-
metastatic activity and make it more likely for the tumor cells to be killed in an immune 
reaction.272 There will also be an increase in activation of dendritic cells, an increase in 
proinflammatory and anti-tumoral cytokines, and promotion of intra-tumoral 
infiltration of cytotoxic cells.284 All these events will make it more likely for a tumor cell 
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to be rejected by the immune system. AXL overexpression is related to development of 
resistance to PD1-inhibition, and the hypothesis is that AXL inhibition will enhance the 
effect of checkpoint inhibitors.285 This is currently in clinical trial (NCT02872259). The 
potential of AXL inhibition in a cancer immunotherapy setting is addressed in a recent 
review, and more research to illuminate this further is of great importance.284 
1.5.1.12 AXL and cancer stem cells 
There is also evidence for a correlation between AXL and CSCs. A study regarding 
breast cancer stem cells (BCSCs) showed that AXL was capable of inducing EMT, by 
upregulating expression of Vimentin and N-cadherin and downregulation of E-cadherin 
in BCSCs.  AXL also regulates the tumorigenicity and ability of invasion and migration of 
BCSCs.286 Cells with high AXL expression also have high surface-expression of CD44, 
which is a known marker of stem-cells. CD44 low cells, have less AXL expression, 





1.6 Vitamin K 
 
Vitamin K was discovered in the 1930s, first described by Henrik Dam, a Danish scientist, 
who received the Nobel prize for the discovery. The major role of the vitamin is to serve 
as a co-factor in γ-carboxylation of glutamic acid residues in specific vitamin K 
dependent proteins (VKDP). The most known VKDPs are related to blood coagulation, 
but they are also found in bone homeostasis and the vasculature, preventing 
calcification.288 The known VKDPs are coagulation factors II, VII, IX and X, protein S, 
protein Z and protein C, and further GAS6, osteocalcin, matrix Gla protein and Gla rich 
protein, together with four unknown integral proteins (PRGP1-4).289  The Gla domain on 
VKDPs gives the proteins the ability to bind metal-ions. After binding of calcium-ions, 
the protein will change structural conformation in the matter of gaining the ability to 
bind to phospholipids. This is necessary for membrane binding, which is a known feature 
of these proteins.290 Dietary supplements of vitamin K is essential. Vitamin K is fat-
soluble, and has several subtypes, where vitamin K1 (phylloquinone) is the most 
available in the human diet, through plant-based nutrients, such as green vegetables, 
grains, fruits and dairy products.291 Vitamin K2 (menaquinone) is synthesized by bacteria, 
and can also be available for humans, either from gut flora bacteria, or from bacteria 
within food, for example cheese, or from liver-products.291,292 Menaquinone is a group 
of proteins, where 7 of the subgroups is considered relevant for human intake 
(menaquinones 4-10). Interestingly, menaquinon-4 can also be produced in 
mammalians, with a conversion of vitamin K1, or other menaquinones.293 This reaction 
is catalyzed by an enzyme called UBIAD1, which was first described in 2010.294 It is 
suggested that vitamin K1 mainly is taken up in the liver, and vitamin K2 in arteries and 
other extra-hepatic locations.289 As vitamin K is taken up in the body in the quinone 
form, it is necessary to convert it to the reduced form, hydroquinone, or vitamin KH2 to 
make it biologically active. This step is catalyzed by the enzyme vitamin K epoxide 
reductase (VKOR), which was first discovered in 2004.295 Alternatively, the reaction 
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could be catalyzed by a more specific NAD(P)H-dependent quinone reductase. This 
enzyme is manly active in the liver.291 The Vitamin K cycle is illustrated in Figure 9. 
The enzyme mediating the γ-carboxylation of glutamic residues is called γ-glutamyl 
carboxylase (GGCX). In the carboxylation reaction, one molecule of Glutamate (Glu) on 
the VKDPs is converted to γ-carboxyglutamate (Gla), at the same time as one molecule 
of vitamin KH2 is converted to its inactive form, vitamin K epoxide. (See figure 9). In the 
conversion of Glu to Gla, one molecule of CO2 is incorporated into the glutamic acid 
binding to γ-carbon.290 To be suitable for reuse as carboxylation substrate, vitamin K 
epoxide has to be converted back to its reduced form, a reaction catalyzed by VKOR.289 
This recycling of vitamin K is preventing clinical vitamin K deficiency in humans, which is 
a rare condition.296 
The liver is the site of synthesis of coagulation factors, and a substantial part of the 
vitamin K in the body are stored here. 10 % of the stored vitamin K is vitamin K1, the rest 
is vitamin K2, mainly MK-7-MK-13.292 The heart and pancreas also contains comparable 
levels of vitamin K1 as in the liver, and lower levels are observed in the brain, kidneys 
and lungs. Vitamin K2 are found at significant levels in the brain, kidney and pancreas.291 
 
Figure 9: Schematic presentation of hepatic vitamin K metabolism. A: In normal conditions. B: In presence of 





Warfarin is one of the most used oral anticoagulants worldwide. Statistics from the 
Norwegian Prescription Database shows that it was approximately 70,000 daily users in 
Norway in 2015.297 Several studies show that the drug is used by approx. 2-10% of the 
adult population, with increasing prevalence with increasing age.298,299  
The clinical available form of warfarin is a racemic mix of equal amounts of (R)- and (S)-
enantiomers, where the S-enantiomers is 3 to 5 times more potent.300 It is almost 
completely absorbed after oral administration and 98-99% is bound to plasma protein, 
especially albumin.301 Warfarin reaches peak plasma concentration after 4 hours.302 It is 
almost completely metabolized in the liver, mostly by CYP2C9.300,301 
Warfarin acts as a vitamin-K antagonist. It interferes with the cyclic conversion of 
vitamin K epoxide to vitamin K. This process is catalyzed by the enzyme vitamin K 
epoxide reductase (VKOR), which is inhibited by warfarin. Consequently, this will stop 
the regeneration of vitamin K from its inactive form, and lead to a depletion of active 
Vitamin K in the body.301,303 Warfarin shares a common ring structure with vitamin KH2, 
and can by binding to VKOR inhibit the reductase reaction.290 There has been a 
discussion if there is a competitive or non-competitive binding of warfarin to VKOR, but 
resent research is suggesting a shared binding site for warfarin and vitamin K, and 
consequently a competitive binding to the enzyme.304 
1.7.1 Cancer protective effects of warfarin in a historical perspective 
 
Reports about anti-cancer effects of warfarin have been published occasionally the last 
50 years. In 1968, Ryan et al reported a reduced incidence of spontaneous metastases 
after Coumadin (warfarin) therapy.305 The group performed a subcutaneous mouse 
model with anaplastic sarcoma and mammary adenocarcinoma, and evaluated the 
development of pulmonary metastases. In both models, there was a significant 
reduction in the metastatic formation in the Coumadin (warfarin) treated group. In the 
early years, the prevailing hypothesis was that the observed cancer protective effect of 
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warfarin was due to anticoagulation effects. This was also supported by observed cancer 
protective effects of other anticoagulants, such as unfractionated, and later, low 
molecular weight heparins.306,307 Brown et al further strengthened the hypothesis of a 
cancer protective effect of warfarin in a publication from 1973.  The group showed that 
warfarin effectively reduced the number of lung metastases in a model of KHT sarcoma 
in mice, and that this effect was abolished when Vitamin K was administered together 
with warfarin. The authors attributes the effect to the coagulation system, and not as a 
direct effect of warfarin on the tumor cells.308 Also McCulloch et al concluded that the 
observed cancer protective effect of warfarin was related to anticoagulation.309 There 
was little knowledge about the molecular effect behind the anti-coagulative properties 
of warfarin during these first years. The connection with warfarin and Vitamin K was not 
properly established until a publication from O’Reilly et al in 1976, where they 
acknowledge the inhibitory effect of warfarin on the conversion of Vitamin K epoxide, 
to Vitamin K.310 In parallel, theories about a direct warfarin effect on the tumor cells 
gradually started to emerge. In 1985, Goeting et al. observed an effect on colorectal 
cancer incidence in rats, both when warfarin was administered in doses affecting the 
coagulation system, but also in a lower, subclinical dose. The authors suggested that the 
observed effect was not related to the coagulation system, rather a molecular effect on 
early stage neoplastic changes.311 The coupling between warfarin and AXL inhibition was 
made in 1999, first from warfarin mediated AXL inhibition of mesangial cell proliferation 
in the kidneys.312  This connection was further established when Tsou et al showed that 
γ-carboxylation was necessary for AXL activation and that this process could be inhibited 
by warfarin115 
1.7.2 AXL and warfarin 
 
As described before, the RTK AXL, is dependent on the vitamin K dependent 
carboxylation of its ligand GAS6 for biological activation. By its inhibition of VKOR, 
warfarin will give a depletion of vitamin K followed by prevented carboxylation of GAS6 
and subsequent inhibited receptor activation.  Non-carboxylated GAS6 will have full 
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capability of binding to the receptor, but will function as a selective AXL-antagonist, as 
it in this state will not be able to induce receptor activation.313 Warfarin has also been 
shown to enhance activity of NK-cells, at doses not affecting the coagulation system.272  
1.8 Health registries 
 
A health register is defined as a “collection of health information, systematically stored 
and organized so it will be possible to retrieve health information about individuals.”314  
In total there are 15 centrally administered health registries in Norway, covering topics 
as birth, drug prescriptions, cancer occurrences and causes of death.315 The registries 
are regulated by the Norwegian law on Health registries, “Lov om helseregistre og 
behandling av helseopplysninger”.316 The free, universal health care system in Norway 
gives the Norwegian health registries a broad, almost complete, coverage. All 
inhabitants of Norway are assigned their own unique identification number, registered 
in the Norwegian National registry, a system in use since 1968.317 The use of this number 
is allowing an individual-level linkage of information from different health registries. This 
gives a wide variety of opportunities to conduct experiments and extract information 
from these sources.  
1.8.1 The cancer registry of Norway 
 
The Cancer registry of Norway (CRN) was established in 1951 and is after the cause of 
death registry the oldest health registry in Norway. The registry is collecting information 
on all cancer cases in Norway, and all medical doctors are instructed by law to notify 
new cancer cases to the registry Also cases with cancer suspicion without verified 
diagnosis, and diagnoses revealed at autopsy should be reported to the registry.318 The 
overall coverage is estimated be over 98%. It records detailed information including 
demographic information, diagnosis, death by cancer, morphology, stage and 
topography. The registry uses International classification of diseases (ICD), ICD-7, and 
ICD-10 for diagnosis classification and the international classification of diseases for 
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oncology, 3rd edition (ICD-O-3), for morphological classification of the different 
lesions.319   
1.8.2 The Norwegian prescription database 
  
The Norwegian prescription database (NorPD) was established in 2004, and collects 
data from all prescribed drugs in Norwegian pharmacies.320 The registry does not 
include information on drugs used by hospitalized or otherwise institutionalized 
patients, nor over the counter drugs, bought without prescription. The registry is using 
the Anatomical Therapeutic Chemical classification system for classification of the 
different drugs.320 When using NorPD for research, the database has several strengths 
compared to other sources of drug use, with no recall bias, and no primary non-




2. Aims of the study 
 
The central hypothesis of this thesis is that AXL mediated signaling is important for the 
development and progression of cancer, and that warfarin-mediated AXL inhibition 
effectively blocks tumor initiation and malignant progression in different cancers.  
Main aim: Characterize the role of warfarin-mediated AXL-inhibition in the 
development and progression of cancer.  
Specific aims: 
Aim I: Conduct AXL inhibition in pancreatic cancer through warfarin mediated 
inhibition of GAS6-carboxylation in different mouse models. (Paper I) 
Aim II: Characterize AXL expression and expression of EMT markers in in vitro 
pancreatic models, with and without AXL inhibition, to investigate the 
relationship between AXL expression and EMT. (Paper I) 
Aim III: Characterize cancer incidence in warfarin users compared to non-users 
to illuminate the potential effect of warfarin-based AXL inhibition in cancer 
development. Conduct a prospective population based cohort study, using the 
Norwegian Cancer registry and the Norwegian prescription database. (Paper II) 
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3. Summary of papers 
 
Paper I 
In this paper, we report that the vitamin-K antagonist warfarin blocks GAS6-mediated 
activation of the receptor tyrosine kinase AXL in different models of pancreatic cancer. 
This inhibition reduces both progression and spread of pancreatic cancer. In vivo 
experiments were performed with human cancer cells and immunocompromised mice, 
murine cells and immunocompetent mice, and with genetically engineered mouse 
models (GEMMs), that spontaneously developed PDAC. In all models, we saw a major 
reduction in the formation of metastases. We also demonstrated an increased effect of 
gemcitabine when given in combination with warfarin, both in primary tumor growth 
and metastatic development. The effect of warfarin mediated AXL-inhibition was 
verified also with other AXL-blocking agents. Through in vitro-experiments, we 
demonstrated that levels of phosphorylated AXL went down after treatment of warfarin. 
In addition, phosphorylation of AKT, downstream of AXL, was increased when 
stimulated with GAS6, and reduced after addition of warfarin. This confirmed that 
warfarin treatment reduced AXL signaling.  Further, the cells ability to form colonies 
were significantly reduced after warfarin treatment, and these results were confirmed 
by AXL-knock down cell lines. We also established the close link between AXL and EMT 
in line with previously published material. Levels of EMT markers were influenced after 
warfarin-mediated AXL-inhibition , with vimentin being downregulated and E-cadherin 
being upregulated in warfarin-treated samples.  
Paper II 
We report in this paper a clear association between warfarin use and cancer. We 
defined a cohort with patients from the Norwegian national registry coupled with the 
Cancer Registry of Norway and the Norwegian Prescription Database to look at the 
incidence of cancer in warfarin users compared to non-users. We observed a 
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significantly lower cancer incidence in the warfarin user group, with an incidence rate 
ratio (IRR) for overall cancer of 0.84 (95% Confidence interval (CI) 0.82-0.87) adjusted 
for sex and age. We further observed a lowered IRR in several of the organ-specific 
cancer sites, such as prostate, lung and bladder cancer. We also performed a subgroup 
analysis on patients prescribed warfarin for atrial fibrillation/flutter (AF-group), to 
eliminate the possible confounding effect of occult malignancy after venous 
thromboembolism and pulmonary embolism. In these analyses the IRR in overall cancer 
were even lowered with an IRR of 0.62 (95% CI 0.59-0.65). Also for specific cancer sites, 
IRR were lowered in the user group compared to the non-users. The findings in this 
study supports the findings from Paper I, and emphasize the potential of warfarin use in 
an anti-cancer setting. 
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4. Methodological considerations  
 
4.1 Animal experiments 
 
The animal experiments in Paper I has been performed with different approaches. In 
the experiments, we have used immunocompetent animals, immunocompromised 
animals and also genetically engineered mouse models (GEMMs) 
4.1.1 Cell line xenograft models 
  
These models depend on the use of human cancer cell lines in mouse models, which is 
a common way of modeling cancer development.322 A prerequisite for this model is the 
use of immunodeficient mice, to prevent rejection of the injected human cells. This way 
of modeling cancer has several challenges. The use of immortalized cell lines will not 
reflect the diversity in a normal tumor, as these cells are preselected cells grown in a 
favorable environment and often with a different gene expression profile than primary 
tumor cells.323 Furthermore, the immune system is important in normal cancer 
development, and in these models, this factor is eliminated. This makes it impossible to 
investigate immune-targeted therapies in this setting. Advantages of this model system 
are the access to numerous and well established cell lines, in many different tumor 
types. These cells can be injected both subcutaneously and orthotopically.  
4.1.2 Syngeneic models 
  
In this model, murine cancer cells are transplanted into mice, using a 
immunocompetent host. With an intact immune system, this will mimic a more realistic 
tumor environment, including stromal cells and tumor vasculature.  Disadvantages of 
the model is that it is less available, as fewer cell lines suitable for the purpose exists. 
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The clinical translation, with both the tumor and the host being of another species than 
human is another challenge.324 
4.1.3 Genetically engineered mouse models  
  
In these cancer models, the mice are genetically altered, so that they spontaneously will 
develop the tumor of interest. This has several advantages with the tumor developing 
in the tissue of origin, and preservation of an intact immune system. The tumor 
microenvironment will also be intact, with all components such as immune cells, 
vascular and stromal cells.325The major disadvantage of this model system is the 
complexity of developing the mouse model.324 
4.2 Mouse strains in use in our work 
  
NOD/SCID: Non-obese diabetics/ Severe combined immunodeficient mice. This mouse 
strain is immunocompromised, due to impaired development of T and B cell 
lymphocytes. In addition, these animals have reduced NK-cells function.326  These mice 
are widely used, both for tumor biology and xenograft research.327 In our work, the 
strain was used for orthotopic implantation of human cancer cell lines.   
 
C57/Bl6: This is an immunocompetent inbred mouse-strain. The strain was first bred in 
the Jackson laboratory in 1948. With a normal immune system, these mice are widely 
used in research in the fields of both immunology and cancer. They are robust and long-
lived compared to other cancer models.328 We used this mouse model, in order to 
implant murine cancer cells, which gave us the ability to study the progression of  PDAC 
in a model with a functioning immune system. 
 
LSL-KrasG12D.; Cdkn2alox/lox.; p48Cre (KIC): Genetically engineered mouse strain. This model 
takes advantage of the pancreas selective transcription factor p48 (Ptf1a). This 
transcription factor drives the expression of Cre in pancreatic cells. The LSL-KrasG12D 
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gives a mutant Kras, which due to the p48 Cre mutation is specifically expressed in the 
pancreas, promoting the development of PDAC. Furthermore, the p16/p19 
(Ink4a/Cdkn2a) locus is deleted, a common mutational loss in human PDAC. This gives 
the tumor an aggressive phenotype, with poorly differentiated tumor cells.329 The 
development of pancreatic carcinoma in this model is 100% at 4 weeks of age. The 
model has histopathological features that is consistent with the development and 
progression of human PDAC, and therefore works well as a model system.330,331 The 
mice were bred in the animal facility of UT Southwestern, Dallas, and genotyped shortly 
after birth.  
We used the following pancreatic cell lines for our experiments: 
Human cell lines:  
AsPc-1: This cell line is derived from cells from the ascites of a patient with pancreatic 
cancer.332 
Panc-1: This cell line was derived from a primary tumor. The cells do not express 
significant amounts of carcinoembryonic antigen.332 
C5LM2: A variant of Panc1 cells. The cell line was developed by two passages of in vivo 
growth and culture of liver metastases from a primary pancreatic cancer. The cell line 
was developed in the Brekken laboratory.  
Mia PaCa2: Cells from primary tumor of pancreatic cancer. This tumor did not express 
carcinoembryonic antigen.332 
Capan1: Derived from a PDAC liver metastasis.332 Capan 1 does not express AXL. 
Included as a control cell line.  
Murine cell line:  
Pan02: Murine cell line, established from pancreatic tumor in a C57/Bl6 strain. Widely 
used for research on pancreatic cancer.333 
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All cell lines for animal experiments were grown in a humidified atmosphere with 5% 
CO2, at 37°C. AsPC-1, Panc-1, Pan02 and MiaPaCa-2 lines were grown in Dulbecco’s 
modified eagle medium (DMEM). Capan-1 cells were grown in Iscove’s modified 
Dulbecco’s medium (IMDM). Before implantation, all cell lines were confirmed to be 
mycoplasma free using e-Myco kit (Boca scientific).  
4.3 In vivo experiments 
  
Animal experiments were performed at University of Texas Southwestern, Dallas, Texas. 
All animals were housed in a pathogen free facility. The animals had 24-hour access to 
food and water.  
All cells were injected orthotopically. For AsPc-1, Panc-1, Mia PaCa2, Capan1 1x106 cells 
were injected, and for Pan02 cells 1x105 cells were injected.  
4.3.1 Medical treatment of  animals 
 
The animals were randomized to receive normal drinking water, or water containing 
warfarin. For immunocompromised mice the warfarin concentration was 1 mg/L 
(3,0μM). Immunocompetent mice received 0,5 mg/L (1,5μM). Warfarin containing 
water was in all cases renewed every 3 days.  The warfarin treatment were administered 
with or without gemcitabine 25 mg/kg twice weekly. For Mia Paca2 tumor bearing mice, 
also 10C9 (250μg ip. twice/week) were given in addition to gemcitabine.  
The GEMMs started warfarin treatment at three weeks of age. The warfarin treatment 
continued for 4 weeks until sacrifice.  
Mice implanted with Panc-1, Capan-1, C5LM2 and Mia Paca2 tumors received warfarin 
therapy for 6 weeks until sacrifice. AsPc1-bearing mice received 4 weeks of therapy. 
Pan02 bearing mice received 3 weeks of therapy. All animals were sacrificed when 
control animals started to be moribund. Differences in aggressiveness and growth rate 
between the models was the reasons for the varying treatment lengths in the different 
models.  
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Dosing of warfarin  
Yanagita et al have shown that warfarin can inhibit GAS6-mediated inhibition of AXL at 
concentrations below those necessary for affecting the coagulation cascade.334 In this 
paper the researchers administered warfarin in drinking water to rats at 0,25-0,5 mg/ml. 
this gave corresponding serum concentrations of 0,28-1,23 μmol/L. No corresponding 
anemia, increased bleeding tendency or prolongation of prothrombin time were 
observed. In Paper I, we administered warfarin in the drinking water with 1mg/L for 
immunocompromised mice and 0,5 mg/ml in immunocompetent mice. The rationale 
for different dosing was an observed toxicity in the immunocompetent mice during pilot 
experiments. We aimed for a dosing with no anticoagulative effect, and no bleeding 
complications were observed during the experiments. 
4.3.2 Measurements of primary tumor burden and metastases 
 
The primary tumor burden was measured by weighing pancreas and tumor en block. 
Metastases were macroscopically counted by visual inspection of liver, diaphragm 
peritoneal surfaces and the abdominal cavity. Metastatic burden was further confirmed 
with H&E staining of liver sections.  
4.4 Induction of EMT 
 
In Paper I, we evaluated the relationship between EMT and AXL, and how AXL expression 
and inhibition would influence on this process.  To establish conditions mimicking EMT, 
cells were grown on chamber slides coated with collagen, and with addition of TGF-β to 
the media. This is an established method to induce EMT in artificial environments, and 
is confirmed by an upregulation of vimentin and a downregulation of E-cadherin.335 
4.5 Register study 
 
In Paper II we performed a register study taking advantage of two of the major health 
registries established in Norway. By using the Norwegian identification number, it was 
possible to couple a cohort from the Norwegian National registry with the Cancer 
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Registry of Norway and the Norwegian prescription database at an individual level. To 
be able to perform the coupling we obtained approval from the following instances, in 
addition to the registries in question:  
Regional Committees for Medical and Health Research Ethics, The Data protection 
official for research at University of Bergen and the Norwegian Data Protection 
Authority. 
4.5.1 The coupling process of different registries 
The coupling of information is possible because of the national identification number. 
The process requires coordination between different instances, in respect of making the 
process as quick and smooth as possible. NorPD is a so-called pseudonymous registry.  
Pseudonymization is the situation where the normal person identifier such as name or 
personal identification number, is replaced with a pseudonym. This pseudonym is 
unique for each individual, but will not have any relation to the original identifier of the 
person.336 Pseudonyms can be used as personal identification in the coupling process. 
Because the process included the NorPD, the coupling process had to end and be 
administered by this registry. Figure 10 illustrates the data collection, and coupling of 
data between the different instances.  
 
Figure 10. Illustration of the coupling process.  




For Paper I, statistical analyses were performed using the software GraphPad Prism 
(GraphPad Prism version 4.00 for windows). Results were expressed as mean +- s.e.m. 
of s.d. Data were analyzed by t-test or ANOVA and results were considered significant 
at p<0.05. 
For Paper II, statistical analyses were performed using the software STATA IC 13.1 and 
STATA IC 14.  
IRRs were calculated by the method of Mantel-Haenzsel, and adjusted for sex and age. 







In Paper I, we evaluated the role of the RTK AXL in PDAC development and metastasis. 
Our findings in this paper supports the hypothesis of AXL being an important driver of 
metastatic formation and cancer progression. Inhibition of AXL leads to decreased 
expression of EMT markers, which further supports the theory of AXL being important 
for the metastatic processes in cancer. Our findings in Paper II supports the preclinical 
findings of the role of AXL in cancer, and shows that AXL also is important in the cancer 
initiation process, as well as in more advanced stages of the disease. 
5.1 The role of AXL in the development and metastasis of pancreatic ductal 
adenocarcinoma 
 
PDAC is one of the most lethal of all cancer forms, with no effective treatment regimen. 
Any research that can contribute to further developments in the treatment of 
pancreatic cancer is highly appreciated. The receptor tyrosine kinase AXL is associated 
with many different cancers, including pancreatic cancer, where AXL overexpression is 
correlated with reduced overall survival and worsened prognosis.244 In the literature, 
AXL has been strongly associated with increased invasiveness, and metastatic 
formation.118,188,337 This is reported also in pancreatic cancer, both from tumor samples, 
and in cell culture experiments.243 AXL inhibition has been suggested as a potential 
treatment option, and different strategies to achieve AXL inhibition includes 
development of small molecule AXL inhibitors, antibody-neutralization of GAS6, the 
ligand of AXL, and as we performed in Paper I, inhibition of γ-carboxylation of GAS6, with 
a subsequent AXL inhibition.157,338 Previous in vitro experiments have demonstrated that 
warfarin strongly inhibits γ-carboxylation of the Gla-domain of GAS6, with a subsequent 
diminished receptor activation.115 Interestingly, the warfarin doses needed for inhibition 
of γ-carboxylation of the Gla-domain on GAS6, are shown to be at levels beneath those 
needed for anticoagulation.272 
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In Paper I, we demonstrated in vitro that warfarin, as expected, inhibited AXL signaling, 
and that this inhibition could be repealed when vitamin K was added to the media. This 
demonstrates that the AXL-inhibitory effect of warfarin are through the depletion of 
Vitamin K. We also observed a decreased expression of GAS6 and γ-carboxyglutamyl 
when the cells where treated with warfarin, which further confirmed the mechanisms 
of action (Paper I, Figure 2 A-B). The levels of active phosphorylated AXL were 
significantly reduced after warfarin treatment, and similarly with treatment with the AXL 
inhibitor BGB324. Nevertheless, warfarin treatment did not influence on the levels of 
total AXL in the cells (Paper I, Figure 2 C). We also observed a decreased signaling in 
phosphorylated AKT downstream of AXL after warfarin treatment, confirming a reduced 
AXL-mediated signal transduction (Paper I, Figure 2 D-E). We further observed a rescue 
effect of pAKT after addition of GAS6. Knowing that AXL expression is correlated with 
increased migration158,286, we conducted a migration assay, showing reduced levels of 
migration in the warfarin treated cells, but only in the AXL expressing cell lines. In Capan-
1 cells, which do not express AXL, we observed no difference in migratory capacity 
(Paper I, Figure 2 F). Altogether these findings confirm that AXL expression is important 
in pancreatic cancer, and that warfarin mediated AXL inhibition will reduce expression 
of both phosphorylated AXL and its ligand GAS6, which will diminish the migratory and 
invasive capacity of the cells. 
Furthermore, we demonstrated in Paper I that warfarin-mediated AXL inhibition 
reduced metastatic formation in vivo, in 5 different murine PDAC models. (Paper I, 
Figure 1B) In a syngeneic and a genetically engineered mouse model we also observed 
a statistically significant effect in primary tumor growth (Paper I, Figure 1A). The findings 
were confirmed, observing similar results using an AXL-knockdown cell line, and by 
selective AXL inhibition by 10C9, an AXL antibody (Paper I, Figure 1 F-G). We also 
observed a reduction in the colony-formation ability of Mia PaCa-2 cells grown in the 
presence of warfarin (Paper I, Figure 3 A-C). The abilities of a cell to grow surface-
independent and form colonies are important features of a cancer cell.339 Our findings 
was in line with previously published material regarding the ability of anchorage 
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independent growth after AXL-inhibition.243 Summarized, our findings establishes AXL 
as a facilitator for the metastatic potential of pancreatic cancer. Pancreatic cancer has 
a high level of metastatic formation, and it has been proposed that inhibition of the 
metastatic process has a great potential in extending life expectancy.340 The results from 
Paper I suggest warfarin-mediated AXL inhibition as a possible treatment option in 
pancreatic cancer. We also observed an increased reduction in metastatic formation 
when warfarin was administered together with the established treatment-option, 
gemcitabine (Paper I, Figure 3 F-I). The enhanced effect of established treatment 
corresponds to what has earlier been described in other cancers, like synergistic effects 
of AXL-inhibition and cisplatin in the suppression of liver metastases in breast cancer, 
and increased cell death in AXL-knockdown cells after treatment with cisplatin, 
carboplatin or doxorubicin in lung carcinoma.157,233 The observed additive effect of 
warfarin and gemcitabine in Paper I increases the potential of warfarin-treatment in a 
clinical setting of pancreatic cancer.  
In Paper I, but also from other groups, it was demonstrated that AXL-inhibition and 
subsequent anti-cancer effects of warfarin could be achieved when administered in 
doses not affecting the coagulation system.272,334 VKDPs located outside the liver are 
shown to be under-carboxylated in the adult population, leaving this population with a 
sub-clinical Vitamin-K deficiency.293 Additionally, it is shown in the liver that another 
enzyme, NAD(P)H-dependent quinone reductase, can function as an alternative 
facilitator for the recovering of vitamin K from the epoxide metabolite, when VKOR is 
inhibited by warfarin.291 Thus, low doses of warfarin will be able to inhibit VKDPs in 
peripheral tissues where the steady state concentration of vitamin K is low, while the 
coagulation-related VKDPs in the liver still will be carboxylated, retaining their biological 
activity. This finding also supports the theory that the cancer protective effect of 
warfarin is not due to anticoagulation effects. The possibility of warfarin administration 
in a low-dose manner is a great advantage for the potential use of the drug in an anti-
cancer setting. The ability of using the drug without unwanted side effects from the 
coagulations system makes it more suitable as a treatment option for cancer patients. 
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In Paper I, we demonstrated a reduction in metastatic growth in all the investigated 
mouse models. However, we also observed an inhibition of primary tumor growth in the 
syngeneic and genetic models. (Paper I, Figure 1A). These models have, in contrast to 
the orthotopic models, an intact immune system.  In normal physiology, AXL is 
important in moderating effects of the immune system and preventing auto-immune 
reactions.156 When AXL is inhibited, the anti-cancer effects are effectuated via two 
systems, both direct tumor effects and indirect immunological effects because of 
repealed AXL-mediated inhibition of the immune system. (Figure 11). 
 
Figure 11: TAM signaling in cancer therapy. Adapted from 284 
Park et al, and later Paolino et al, demonstrated an increased cytotoxic ability of NK-
cells, after AXL inhibition.272,341 However in a recent paper, the researchers argue that 
AXL signaling will increase effector function of NK cells, so this remains still debated.342 
In the model systems in Paper I, the orthotopic models will only benefit from the direct 
tumor effects seen in figure 11, as these mice are not immunocompetent. The syngeneic 
and genetically engineered models will benefit both from the direct tumor effects, but 
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also from immunological effects on the tumor. This could explain the observed effects 
also on primary tumors in these models.  
5.2 The role of EMT in warfarin-mediated AXL-inhibition in pancreatic cancer 
 
It has been thoroughly documented that AXL is closely related to the process of 
EMT.65,286,343 Known EMT-inducers, such as TWIST, will upregulate AXL. At the same 
time, it is shown in pancreatic cancer, that AXL expression contributes to maintenance 
of the levels of EMT-inducers such as SNAIL, SLUG and TWIST.157,243 This is suggesting a 
positive feedback loop, where EMT-inducers upregulate AXL, and AXL at the same time 
is maintaining the levels of the inducers. We hypothesized that the observed effect of 
warfarin-mediated AXL-inhibition in pancreatic cancer in Paper I, was related to an 
inhibition of the EMT process. A blocking of EMT is shown to decrease the metastatic 
potential and the migratory ability of a developing tumor, in a wide range of tumors, 
including pancreatic cancers.344,345 However, a report from 2015 claims that EMT 
suppression will not limit the metastatic development in pancreatic cancer. In a mouse 
model with deletion of the EMT-inducers SNAIL or TWIST, the group observed no 
change in the metastatic potential of the tumors.346 Previously, it has also been a 
challenge to find consistent evidence of upregulation of mesenchymal markers, and 
downregulation of epithelial markers in this setting, with a high variability of expression 
between tumors. 347 An explanation of this variability is the theory that not all cancer 
cells undergo EMT at the same time, resulting in cells within a certain tumor presenting 
with different levels of EMT at a given time-point. According to this theory, only a small 
fraction of the cells in a certain tumor will have gained mesenchymal properties and are 
presenting with detectable mesenchymal markers as evidence for EMT.96,344 
In Paper I, we investigated the relationship between EMT and AXL expression in 
pancreatic cancer. We found, as expected, that EMT induction by collagen and TGFβ, 
gave an increase in AXL phosphorylation, and also increased expression of ZEB1 and 
nuclear β-catenin, and that this effect was blocked when warfarin was added. We also 
experienced increased levels of the mesenchymal markers Vimentin and ZEB1 with 
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addition of GAS6 to AXL-expressing cells. Furthermore, we observed a downregulation 
of the mesenchymal marker Vimentin, and a simultaneous increase in the epithelial 
marker E-cadherin after warfarin treatment (Paper I, Figure 4 A-C). These results support 
previous reports about EMT in pancreatic cancer348 and contributes with evidence to 
the theory that EMT is a strong regulator of the invasive and metastatic potential of 
pancreatic tumors.  
5.3 Vitamin-K in cancer 
 
Warfarin is inhibiting AXL by inhibiting the conversion of oxidized vitamin K to the active 
reduced vitamin K. This process is catalyzed by the enzyme VKOR. When this enzyme is 
inhibited, there will be a depletion of active vitamin K in the body (See section 1.6, figure 
9). Active vitamin K is a necessary substrate for the GGCX enzyme, which converts 
glutamate to γ-carboxyglutamate at the Gla-domain of VKDPs. This conversion is 
necessary for the biological function of VKDPs. 349 This has been demonstrated for AXL-
GAS6 specifically, where γ-carboxylation of GAS6 is shown to be required for ligand-
induced receptor activation.110,132,350 Non-carboxylated GAS6 retains full AXL-binding 
affinity, but is not capable of inducing receptor activation.283 This is converting the ligand 
into an AXL antagonist. Interestingly, upregulation of GGCX is observed together with 
upregulation of AXL/GAS6 in several different cancers, facilitating a high receptor 
activity.283 
Our findings from paper I and paper II proposes a cancer-promoting relationship 
between vitamin K and cancer, related to γ-carboxylation of GAS6 and subsequent AXL-
activation. Nevertheless, there are some contradictory findings regarding Vitamin K and 
its role in cancer development. Some studies has shown that intake of menaquinon-4 
(MK-4), an isoform of Vitamin-K, could have a cancer protective effect, especially in liver 
cancer.291 The mechanisms behind this effect are poorly understood, without any 
defined molecular target, although an impact of cell cycle has been proposed.351 MK-4 
constitutes only a small fraction of dietary vitamin K, and it is not likely that the proposed 
cancer protective effect would have any impact of the results from Paper II. In that case, 
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it would give rise to more cancers in the warfarin treated group, as MK-4 also would be 
inhibited by warfarin.  
5.4 Warfarin use and cancer incidence 
 
Based on our findings from Paper I, we asked the question if warfarin could influence on 
cancer incidence in humans. To address this we performed a register based cohort 
study, using data from the comprehensive Norwegian health registries. The free, 
universal health care system in Norway ensures that these registries have broad 
coverage and are well suited to be basis for a population study. The vitamin-K antagonist  
warfarin is a drug that is commonly administered in the adult population, most 
prevalent over 50 years of age, and as described in the introduction, with increasing 
prevalence with increasing age.299  
The most widespread effect of increased AXL expression is related to cancer progression 
and metastatic dissemination. AXL overexpression could also be important in the 
process of tumor initiation.  Asiedu et al published in 2014 results demonstrating that 
AXL expressing cells is more tumorigenic than AXL-negative cells.286 This is in line with 
demonstrated effects on tumorigenesis also in other cancers, such as pancreatic cancer, 
prostate cancer and glioblastoma.103,263,352 After primary tumor is established, effects 
on tumor growth have been demonstrated in many tumor forms, such as PDACs and 
glioblastomas. In other tumors, primary tumor growth is less or not affected.353 
Several reports have been published on warfarin use and cancer, both clinical trials and 
register-based studies. The results have been somewhat conflicting. In 2011, Pengo et 
al published a report assessing the effect of warfarin treatment on cancer incidence and 
survival in a cohort of 76,008 persons. They found a Hazard ratio (HR) of newly 
diagnosed cancer of any type in the exposed group of 0.88, and a HR of 0.69 in prostate 
cancer.354 These findings correspond to our findings in Paper II, with an IRR of 0.84 in 
all-site cancer, and 0.69 in prostate cancer (Paper II, Table 2). Contradictory, Kinnunen 
et al evaluated the risk of prostate cancer in warfarin users in a Finnish population of 
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78,615 men. In this study they reported an elevated risk of prostate cancer in warfarin 
users compared to non-users, with  an adjusted HR of 1.11.355 To define warfarin users, 
they took into consideration any use of warfarin prior to cancer diagnosis, also 
prescriptions made shortly before diagnosis, when it is likely that the cancer was already 
established. This could be a source to overestimation of cancer cases in the user group. 
Due to the wide definition of a warfarin user, they define 16.7 % of their population as 
warfarin users, compared to 7.4 % in the population in our study (Paper II, Table I). An 
estimate of 16.7 % users in the investigated population is high also considering the 
prevalence in the general population, which has been reported to be approximately 3 
% in a general population, and 9 % in a population older than 65 years.298  
The opportunity to perform a register based population study, with a large cohort gives 
a unique possibility to investigate the question of anti-cancer effects of warfarin in a 
large scale. One of the major limitations of a study based on the major health registries 
in Norway is the lack of information of possible confounding factors in the material. The 
available information includes demographic information, and information extracted 
from the registries in question, the CRN and NorPD. The registries do not contain any 
information regarding lifestyle factors as food intake, physical activity, smoking or 
alcohol use. These are factors that potentially could influence on the risk of cancer 
development. However, the properties of broad-covering registries allow inclusion of a 
great number of individuals, which makes it possible to perform analyses, also on rarely 
occurring cancer forms.356 This is a major advantage with large cohorts, and it has to be 
considered together with the concurrent limitation of lack of information on life style 
factors.  
 
In Paper II, we observed an overall cancer protective effect, although the effect was not 
consistent for every included cancer site in the material. We observed that our findings 
corresponds to cancers with a known close relation to AXL, such as lung, prostate and 
breast.157,234,263 In Paper II, table 2, we see that there is no significant warfarin protective 
effect for overall Bone-marrow related cancer, or leukemia as a group of diseases. 
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Nevertheless, for AML, we observe a significant IRR of  0.82. Up-regulation of AXL is 
shown to be closely related to a worsened prognosis and poor survival in AML.218 AXL 
upregulation is shown in a much lesser extent in the lymphoid leukaemias.220 Based on 
the hypothesis of the warfarin-AXL relationship, we did not expect a major reduction of 
the incidence of lymphatic leukaemias after warfarin treatment. Consistent with this, in 
the results from Paper II, we observe a cancer-protective effect of warfarin in AML, and 
on the other hand, there is no significant difference in the incidence of CLL in warfarin 
users compared to non-users. (Paper II, Table 2).  
It is known that thromboembolic disease, such as venous thromboembolism and 
pulmonary embolism, is associated with an elevated cancer risk. The risk is highest the 
first year after diagnosis, but an increased risk has been shown also later.357 This was an 
important confounding factor in our study, which needed to be addressed. Thus, we 
also evaluated the cancer risk in a subgroup of the warfarin-users, which were 
prescribed warfarin after atrial fibrillation or flutter. This group lacked the preexisting 
occult malignancy risk of the thromboembolic patients. In this group, we observed an 
overall IRR in the users of 0.62 (Paper II, Supplementary Table 2). This reduction in IRR 
was expected, and in line with the knowledge of an increased cancer risk in the 
thromboembolic patients.  
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5.6 Warfarin in the era of Non-vitamin K anticoagulants 
 
In the recent years, a new class of anticoagulant drugs has emerged, so-called non-
vitamin K anticoagulants (NOACs). The drug-class consists of four different drugs. 
Dabigatran is targeting thrombin, Apixiban, Edoxaban and Rivaroxaban are targeting 
factor Xa.358,359 The use of NOACs as a replacement for warfarin has some important 
advantages. NOACs do not require regularly laboratory monitoring, as the therapeutic 
window has a wide range. There are also fewer interactions between food and other 
drugs, which gives a more stable bioavailability, with reduced risk of being outside the 
therapeutic range.360 At the same time, NOACs are shown to be as effective, or even 
superior to warfarin in reducing the risk of thromboembolic events after atrial 
fibrillation. The risk of side effects are similar to warfarin, with no difference regarding 
major bleedings, but with an increase in gastrointestinal bleedings.361  In Paper II, we 
propose a cancer protective effect of warfarin, with a 16 % lower risk of all-site cancer 
in the users compared to non-users. For selected cancer sites, the observed protective 
effect is further lowered, with a 20% lower IRR in lung cancer and 31% lower IRR in 
prostate cancer compared to controls. (Paper II, table 2) Based on the results from Paper 
II, the switch from warfarin to other anticoagulation regimen could have the potential 
to give an increase in cancer incidence, affecting millions of patients on a world basis. 
The loss of a specific cancer protective effect of warfarin should be taken into 




6. Concluding remarks 
 
Based on our findings, we claim that the RTK AXL is an important facilitator for 
pancreatic cancer metastatic dissemination and outcome. Warfarin-mediated AXL-
inhibition is shown in vivo to effectively prevent or decrease metastatic formation in 
different model systems. We also show that the observed cancer-protective effect is 
achieved when warfarin is administered in doses not affecting the coagulation system. 
We show that AXL expression is strongly related to the EMT process in pancreatic 
cancer, and that warfarin mediated AXL-inhibition will reverse the EMT process, and 
increase the expression of epithelial markers, and recover epithelial properties in the 
cells.   
In a register-based cohort study, we also show that warfarin-use is associated with 
lowered cancer incidence in a large Norwegian cohort. The cancer protective effect of 
warfarin is observed both for overall cancer, and also for several cancer sub-sites. We 
hypothesize that the observed association is due to warfarin-mediated AXL-inhibition 
in the cancer cells. Our findings in Paper II show a broad cancer protective effect of an 
old, commonly used drug. Our findings from Paper I, suggests that it would be possible 
to obtain warfarin-mediated cancer protection also in low doses, not affecting the 
coagulation system. These findings should be taken into consideration in the era of 
NOACs, when the choice of anticoagulant therapy is to be made.  Further studies are 
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7. Future perspectives 
 
The RTK AXL is known to have important roles in normal physiology, mostly related to 
hemostasis, phagocytosis of apoptotic cells, and dampening of the immune system. 
Collectively, the role of the receptor appears to be related to maintenance of body 
homeostasis, such as resolving inflammation response. The role of AXL in cancer is 
somewhat paradoxical to this pattern. In cancer, AXL signaling lead to increased stress, 
for example through enhanced invasiveness, migration and prolonged cell survival, 
even of highly atypical cells. The relevance of AXL’s role in normal physiology as 
applied to the cancer setting is not very well described.  It seems that AXL-mediated 
contributions to normal tissue homeostasis are effectively co-opted by cancer cells to 
mitigate stress during tumorigenesis. We know that cancer-related AXL-effects are 
associated with AXL upregulation, and very rarely are the result of mutations. One 
hypothesis is that the pro-tumor effects of AXL require a certain degree of dynamic 
expression. Indeed a recent paper describes the existence of rare tumor cells that 
sporadically express high AXL levels (“AXL jackpot cells”) that are the source of 
resistant colonies.362 Importantly, these cells are not genetically fixed but rather 
transition into an AXL-expression state only when necessary. Future research on this 
conversion would be of interest, to clarify how the levels of AXL reflect changes in the 
surrounding microenvironment.   
We have also established the role of warfarin as an AXL-inhibitor. This 70-year old drug 
is widely used as an anticoagulant, but has on occasions been proposed as an anti-
cancer drug. Based on the results from this thesis we propose a potential use for 
warfarin in the anti-cancer setting. The possibility to use the drug at sub-coagulation 
doses further strengthens the potential for use as cancer prevention. Further 
experiments, to elucidate the potential benefits of the drug would be of great interest. 
In our register-material we have the possibility to look into cancer-specific survival in 
warfarin users compared to non-users, and this is a natural step following the 
experiments of this thesis. Furthermore, after the implementation of NOACs as 
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alternative anticoagulation regimen, it will be possible to perform a register study that 
compares cancer incidence in warfarin users versus users of NOACs. This could more 
definitively differentiate the coagulation-independent anti-cancer properties of 
warfarin, and a study with this focus is in planning.  
We have hypothesized that warfarin have an effect in the tumor initiation phase. To 
take advantage of this effect clinically, it would be necessary to start warfarin 
treatment before the start of cancer development. This would imply a widespread 
treatment of a healthy population, and could be a challenge both ethically, logistically, 
and from a socioeconomical perspective. Nevertheless, it could be interesting to 
administer the drug in an adjuvant setting, to exploit the proposed effect of tumor 
initiation to prevent recurrent disease.  
Overall, further defining the role of AXL in cancer development and the cancer 
protective effects of AXL inhibition are warranted. Future steps would be both on a 
pre-clinical and register-based level, but also eventually translation into clinical trials to 
establish the overall cancer-protective potential for using warfarin-mediated AXL-
inhibition in a clinical setting.  
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